

Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Review

Contents lists available at ScienceDirect

International Immunopharmacology



journal homepage: www.elsevier.com/locate/intimp

Acute kidney injury and renal replacement therapy in COVID-19 patients: A systematic review and meta-analysis



Xiaopeng Yang^{a,1}, Shasha Tian^{a,1}, Hui Guo^{a,b,*}

^a Department of Nephrology, The Second Hospital of Shanxi Medical University, Taiyuan, Shanxi 030001, China
^b Department of Nephrology, The Shenzhen Baoan Shiyan People's Hospital, Shenzhen, Guangdong 518005, China

RTICLE INFO	A B S T R A C T
eywords: OVID-19 cute kidney injury enal replacement therapy	<i>Purpose</i> : Reported rates of acute kidney injury (AKI) have varied significantly among studies of coronavirus disease 2019 (COVID-19) published to date. The present meta-analysis was conducted to gain clarity regarding AKI incidence and renal replacement therapy (RRT) use in COVID-19 patients. <i>Methods</i> : The PubMed, Embase, Web of Science, medRxiv, and bioRxiv databases were systematically searched for COVID-19-related case reports published through 25 July 2020. Pooled analyses were conducted using R. <i>Results</i> : The pooled incidence of AKI in 51 studies including 21,531 patients was 12.3% (95% CI 9.5–15.6%), with higher rates of 38.9% in 290 transplant patients (95% CI 27.3–51.9%), 39.0% in 565 ICU patients (95% CI 23.2–57.6%) and 42.0% among 1745 deceased patients (95% CI 30.3–54.7%). RRT usage was reported in 39 studies of 17,664 patients, with an overall pooled use of 5.4% (95% CI 4.0–7.1%), with higher rates of 15.6% in 117 transplant patients (95%CI 9.9–23.8%) and 16.3% in 776 ICU patients (95% CI 11.1–23.3%). <i>Conclusion:</i> AKI and RRT use among COVID-19 patients represent a major public health concern, and early and appropriate intervention should be called upon to improve the prognosis of patients suffering from AKI.

1. Introduction

Within the past two decades, two previously unknown coronaviruses known as severe acute respiratory syndrome coronavirus (SARS-COV) and Middle East respiratory syndrome coronavirus (MERS-COV) have caused serious epidemic outbreaks associated with high mortality rates [1,2]. A new form of pneumonia associated with a novel coronavirus emerged in late 2019 in Wuhan, China [3], and rapidly began spreading between humans after initial local spread in a seafood market. The disease caused by this novel SARS-related coronavirus (SARS-COV-2), which was designated coronavirus disease 2019 (COVID-19), was declared a global pandemic by the World Health Organization in March 2020. As of July 31, 2020, over 17 million COVID-19 cases and 670,000 deaths associated with this virus had been reported [4]. Early symptoms of COVID-19 include fever, a dry cough, and dyspnea [5]. The disease can progress rapidly and can cause high rates of mortality or severe lifethreatening organ damage in some patients.

One retrospective analysis of 536 SARS patients found that while acute kidney injury (AKI) was uncommon among these patients (36 cases), its incidence was associated with a 91.7% mortality rate [6]. A male patient that died of acute pneumonia and renal failure in Saudi Arabia in 2012 was the first patient from whom MERS-CoV was isolated [2], underscoring the potential for severe renal damage associated with these viruses. Xu et al. [7] determined that SARS-CoV and SARS-CoV-2 are highly homologous, and computational models revealed that SARS-CoV-2 exhibits a strong affinity for human angiotensin-converting enzyme 2 (ACE2). There is evidence to suggest that COVID-19 infection has the potential to induce kidney damage in infected patients. For example, Li et al. [8] found that blood urea nitrogen was elevated in 30.1% (59/193) of analyzed COVID-19 patients, while creatinine levels were elevated in 22.3% (43/193) of these patients. These same patients also frequently exhibited proteinuria (59.9%; 88/147) and hematuria (48.3%; 71/147), and most exhibited abnormal renal radiographic findings consistent with edema and inflammation. AKI incidence in COVID-19 patients has also been found to be an independent predictor of poor prognosis and elevated mortality rates [9]. Chan et al. reported a high pooled mortality rate of 93.27% among 65 patients with AKI [10]. In the present study, we thus undertook a comprehensive approach to

E-mail address: ghty966@hotmail.com (H. Guo).

https://doi.org/10.1016/j.intimp.2020.107159

Received 10 September 2020; Received in revised form 7 October 2020; Accepted 26 October 2020 Available online 3 November 2020 1567-5769/© 2020 Elsevier B.V. All rights reserved.

^{*} Corresponding author at: Department of Nephrology, The Second Hospital of Shanxi Medical University, No.382, Wuyi Road, Xinghualing District, Taiyuan, Shanxi, China.

¹ Xiaopeng Yang and Shasha Tian contributed equally to this article.



Fig. 1. PRISMA flow diagram.

reviewing relevant literature to conduct a systematic review and metaanalysis regarding rates of AKI and renal replacement therapy (RRT) use among COVID-19 patients.

2. Methods

The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) Statement and Meta-analysis of Observational Studies in Epidemiology (MOOSE) guidelines were used to guide the conceptualization and execution of this meta-analysis [11,12].

2.1. Search strategy

The PubMed, Embase, Web of Science, medRxiv, and bioRxiv databases were systematically searched for relevant studies published as of 25 July 2020, without any language restrictions, using the following

Table 1

Characteristics of included studies.

NameNameNomNameNa	Study	Location	Study design	Ν	Average age	Male	AKI(total)	AKI(ICU)	AKI(death)	RRT(total)	RRT(ICU)
NumN	Wang2020[13]	China	ROS	138	56	75 (54.3%)	5 (3.6%)	3 (8.3%)		2 (1.5%)	2 (5.6%)
Richards 2020 [15]GNANOSAI <t< td=""><td>Wang 2020 [14]</td><td>China</td><td>POS</td><td>116</td><td>54</td><td>67 (57.8%)</td><td>0</td><td>0</td><td></td><td></td><td></td></t<>	Wang 2020 [14]	China	POS	116	54	67 (57.8%)	0	0			
Hang 2020 [16]ChinaNGN4149307.2%)37.2%)<	Richardson 2020 [15]	USA	ROS	5700	63	3437 (60.1%)	1370 (24.0%)		347 (62.7%)	225 (3.9%)	
Cheng 2020 1/7ChinaPoinPOIG3G7 (52.4%)G3 (51.8%)JLLL <t< td=""><td>Huang 2020 [16]</td><td>China</td><td>ROS</td><td>41</td><td>49</td><td>30 (73.2%)</td><td>3 (7.3%)</td><td>3 (23.1%)</td><td></td><td>3 (7.3%)</td><td>3 (23.1%)</td></t<>	Huang 2020 [16]	China	ROS	41	49	30 (73.2%)	3 (7.3%)	3 (23.1%)		3 (7.3%)	3 (23.1%)
Chen 2000 [16]ChinaRoba2746217 (62.4%)20 (10.6%) <th< td=""><td>Cheng 2020 [17]</td><td>China</td><td>POS</td><td>701</td><td>63</td><td>367 (52.4%)</td><td>36 (5.1%)</td><td></td><td></td><td></td><td></td></th<>	Cheng 2020 [17]	China	POS	701	63	367 (52.4%)	36 (5.1%)				
Grann 2002 [19] China RoS 199 42 640 (35.2%) 6 (0.5%)	Chen 2020 [18]	China	ROS	274	62	171 (62.4%)	29 (10.6%)		28 (24.8%)	3 (1.1%)	
Alberic Intaly Rols 20 59 16 (80.0%) 6 (30.0%) ····· 1 (5.0%) J Zhou 2020 [24] China ROS 19 52 57.357 35 (67.3%) 15 (28.4%) 15 (28.4%) 12 (27.5%) 9 (17.3%) 9 (17.3%) Zhou 2020 [24] China ROS 21 70 11 (52.4%) 4 (19.1%) 4 (19	Guan 2020 [19]	China	ROS	1099	42	640 (58.2%)	6 (0.5%)			9 (0.8%)	
Yang 2020 [21] China ROS 52 59.7 35 (67.3%) 15 (28.8%) 12 (27.9%) 9 (17.3%) 1 (10.52%) 9 (17.3%) 9 (17.3%) 1 (10.52%) 9 (17.3%) 1 (10.52%) 9 (17.3%) 1 (10.52%) 9 (17.3%) 1 (10.5%) 9 (17.3%) 1 (10.5%) 9 (17.3%) 1 (10.5%) 9 (17.3%) 1 (10.5%) 1 (10.5%) 1 (10.5%) 1 (10.5%) 1 (10.5%) 1 (10.3%	Alberici 2020 [20]	Italy	ROS	20	59	16 (80.0%)	6 (30.0%)			1 (5.0%)	
Zhong 2020 Chuma Rols 19 56 119 66.23%) 28 (1.4, 7%) 27 (50, 9%) 10 (5.2, 8%) Acemiz 2020 China ROS 21 70 11 (5.2, 4%) 4 (19, 1%) 4 (19, 1%) 4 (19, 1%) Banerjee 2020 China ROS 28 NR 124 (55, 1%) 20 (18, 3%) 1 (2, 9%) 1 (6, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 116 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%) 3 (16, 7%)	Yang 2020 [21]	China	ROS	52	59.7	35 (67.3%)	15 (28.8%)	15 (28.8%)	12 (37.5%)	9 (17.3%)	9 (17.3%)
Chen 200 [24] China R0S P3 S.5. 67 (67.7%) 3 (3.0%) P (3.1%) Banerje 2020 [25] UK R0S 7 47.6 4 (57.1%) 4 (57.1%) 20 (18.3%) >	Zhou 2020 [22]	China	ROS	191	56	119 (62.3%)	28 (14.7%)		27 (50.0%)	10 (5.2%)	
Arentz 2020 [24] USA ROS 21 70 11 (52,4%) 4 (19,1%) USA USA <thusa< th=""> USA <thusa< th=""> USA USA</thusa<></thusa<>	Chen 2020 [23]	China	ROS	99	55.5	67 (67.7%)	3 (3.0%)			9 (9.1%)	
Banerge 2020 [2:5] UK K0S / 9 47.5 4 (5.71%) 4 (5.71%) 2 (15.3%) 2 (15.3%) 2 (15.3%) Guo 2020 [2?] China R0S 187 58.5 9 (48.7%) 18 (9.6%) 2 (12.202) [23] China R0S 416 64 205 (49.3%) 8 (1.9%) 2 (13.3%) 4 (3.7%) 4 (5.7%) 2 (0.5%) 2 (15.3%) 14 (73.7%) 4 (5.7%) 2 (0.5%) 2 (13.3%) 14 (73.7%) 4 (5.7%) 2 (0.5%) 2 (13.3%) 14 (73.7%) 4 (5.7%) 2 (0.5%) 2 (13.3%) 14 (73.7%) 4 (5.7%) 2 (10.3%) 4 (5.7%) 4 (5.7%) 2 (10.7%) 4 (10.7%) 2 (10.7%	Arentz 2020 [24]	USA	ROS	21	70	11 (52.4%)	4 (19.1%)	4 (19.1%)			
Deng 2020 [26] Chinia ROS 2.2 NR 1.4 (12, 5), 19 20 (18, 39) 20 (18, 39) Lei 2020 [26] China ROS 34 55. 91 (44, 7%) 81 (9, 6%) 2 (13, 3%) 1 (2, 9%) 1 (2, 9%) 1 (2, 9%) 1 (2, 7%) Wang 2020 [30] China ROS 107 51. 57 (53, 3%) 14 (13, 15%) 4 (73, 7%) 4 (3, 7%) 5. Zhang 2020 [32] China ROS 221 56. 108 (48, 9%) 10 (4, 5%) 10 (38, 5%) 72 (22, 3%) 4 (15, 4%) Brill 2020 [33] China ROS 102 76 (65, 14%) 17 (5, 3%) 10 (38, 5%) 72 (22, 3%) 4 (15, 4%) Piva 2020 [35] USA ROS 102 76 (30, 9%) 1 (10, 9%) 24 (9, 9%)	Banerjee 2020 [25]	UK	ROS	7	47.6	4 (57.1%)	4 (57.1%)		00 (10 00/)		
Guo 2000 [27] China ROS 187 58.5 91 (48.7%) 18 (9.5%) 2 (13.3%)	Deng 2020 [26]	China	ROS	225	NR	124 (55.1%)	20 (8.9%)		20 (18.3%)		
Lin 2002 [24] China ROS 34 55 14 (41.278) 2 (19.79) 2 (13.79) 1 (2.799) 1 (2.799) 1 (2.799) Wang 2020 [30] China ROS 107 51 57 (53.39) 14 (13.19) 1 4 (73.79) 4 (3.79) 2 (2.39) Zhang 2020 [32] China ROS 625 NR 328 (50.99) 2 (0.59) 5 (31.29) 7 (2.239) 0 4 (15.49) Wang 2020 [32] China ROS 645 NR 328 (50.99) 2 (0.59) 10 (38.5%) 5 (31.29) 4 (15.4%) Brill 2020 [34] UK ROS 322 61 16 (6 (1.4%) 15 (16.0%) 5 (31.2%) 1 (3.4%) 1 (3.4%) Via 2020 [35] USA ROS 102 7 (2.20.%) 1 (10.0%) 1 (3.4%) 1 (3.4%) 1 (3.4%) Via 2020 [36] USA ROS 820 NR 511 (60.1%) 28 (3.39) 184 (78.0%) 1 (3.4%) 1 (3.4%) Argenziano 2020 [40] India ROS 32 54.5 19 (59.4%) 13 (40.6%) 1 (3.3%) 5 (3.7%) 1 (3.3%) 5 (3.7%) 1 (3.3%) 1 (3.4%)	Guo 2020 [27]	China	ROS	187	58.5	91 (48.7%)	18 (9.6%)	0 (10 00/)		1 (0.00/)	1 ((70/)
Jin 2020 [29] Linia ROS 1/0 0/4 205 (9.5.9) 6 (1.5.9%) 14 (13.1%) 14 (73.7%) 2 (3.7%) Zhang 2020 [31] China ROS 221 55 106 (48.9%) 10 (4.5.9%) 5 (2.3%) 5 (2.3%) Zhang 2020 [32] China ROS 645 R 328 (50.9%) 10 (38.5%) 7 (2.2.9%) 4 (15.4%) Zhang 2020 [35] UK ROS 450 7 22 (26.4%) 85 (18.9%) 5 (4.31.2%) 7 (2.2.9%) 4 (15.4%) Piva 2020 [37] Indy POS 33 64 30 (90.9%) 10 (38.5%) 24 (9.9%) 13 (3.8%) Argenzino 2020 [37] Indy POS 33 64 30 (90.9%) 14 (73.0%) 14 (73.7%) 4 (15.4%) 17 (13.4%) Argenzino 2020 [37] Indy POS 33 64 30 (90.9%) 184 (78.0%) 184 (78.0%) 10 (13.7%) 16 (13.7%) Argenzino 2020 [37] India ROS 32 54.5 19 (59.4%) 13 (4.0.6%) 10 (13.7%) 16 (13.7%) 16 (13.7%) Argenzina 2020 [40] India <td< td=""><td>Lei 2020 [28]</td><td>China</td><td>RUS</td><td>34 416</td><td>55</td><td>14 (41.2%) 205 (40.2%)</td><td>2 (5.9%)</td><td>2 (13.3%)</td><td></td><td>1 (2.9%)</td><td>1 (6.7%)</td></td<>	Lei 2020 [28]	China	RUS	34 416	55	14 (41.2%) 205 (40.2%)	2 (5.9%)	2 (13.3%)		1 (2.9%)	1 (6.7%)
$ \begin{array}{ $	Sill 2020 [29] Wang 2020 [20]	China	RUS	410	04 E1	205 (49.3%)	8 (1.9%) 14 (12 104)		14 (72 704)	2 (0.5%)	
Jamag 2020 [31] Clinia ROS 2.11 S.D. Ref 9.79 Ref 9.79 Form Section Section Jamag 2020 [32] Clinia ROS 323 61 166 (51.4%) 17 (3.8%) 10 (38.5%) 72 (2.9.%) 4 (15.4%) Brill 2020 [35] USA ROS 10 79.7 22 (6.0%) 11 (10.0%) 24 (9.9%) - Piva 2020 [37] Iaiy POS 33 64 30 (90.9%) - 1 (3.4%)	7hang 2020 [30]	China	ROS	201	55	108 (48 0%)	14 (13.1%)		14 (73.7%)	4 (3.7%) 5 (2.3%)	
Jamag 2040 [24] Clinia ROS OHD NK Date State Sta	Zhang 2020 [31]	China	ROS	645	35 NP	108 (48.9%) 328 (50.0%)	10(4.3%)			5 (2.5%) 0	
Intraction (3.2) China ROS 4.2.3 0.1 ROS (3.7.4) P(13.7.4) P	Linalig 2020 [32]	China	ROS	333	61	166 (51 4%)	2 (0.3%)	10 (38 5%)		0 72 (22 30%)	4 (15 4%)
Dame 2020 [35] USA ROS 1.03 7.2 2.2 (20.7%) 5.7 (21.2.7%) 5.7 (21.2.7%) Salacup 2020 [35] USA ROS 242 66 123 (50.8%) 242 (50.7%) 1 (10.0%) 213 (50.3%) 1 (3.4%) 1 (3.4%) Piva 2020 [35] USA ROS 850 NR 511 (60.1%) 288 (33.9%) 184 (78.0%) 117 (13.8%) 83 (35.2%) Anish 2020 [39] Canada ROS 12 54.5 19 (50.4%) 13 (40.6%) 117 (13.8%) 83 (35.2%) Aggarwal 2020 [41] USA ROS 242 66 123 (50.8%) 2(3.7%) 5 (3.7%) 10 (21.7%) 10 (21.7%) 10 (3.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 12 (20.14%) 12 (20.14%) 12 (20.14%) 12 (20.14%) 12 (20.14%) 12 (20.14%) 12 (20.14%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (21.7%) 10 (3 (2.0%)	Brill 2020 [34]	UK	ROS	450	72	272 (60.4%)	85 (18 0%)	10 (30.370)	54 (31.2%)	/2 (22.3/0)	+ (13.+70)
$ \begin{array}{c ccccccccccccccccccccccccccccccccccc$	Cheung 2020 [35]	USA	ROS	10	79.7	2 (20.0%)	1 (10.0%)		54 (51.270)		
Piva 2020 [37] Italy POS 33 64 30 (90.9%) 10 (3.0%) 1 (3.4%) 1 (3.4%) 1 (3.4%) Argenziano 2020 [38] USA ROS 850 NR 511 (60.1%) 288 (33.9%) 184 (78.0%) 117 (13.8%) 83 (35.2%) Anish 2020 [40] India ROS 32 54.5 19 (59.4%) 13 (40.6%) 26 (10.7%) 16 (13.7%) Haydar 2020 [41] USA ROS 242 66 123 (50.8%) 26 (10.7%) 5 (3.7%) Wan 2020 [43] China ROS 135 47 7 2 (53.3%) 5 (3.7%) 5 (3.7%) 5 (3.7%) Wan 2020 [44] Poland ROS 15 51 10 (66.7%) 6 (40.0%) 10 (21.7%) 18 (4.8%) Hardy 2020 [46] USA ROS 15 51 10 (66.7%) 6 (40.0%) 20 (26.1%) 21 (20.1%) Greep 2020 [47] Spain ROS 2226 61 1074 (48.2%) 173 (7.8%) 120 (26.1%) 21 (20.1%) 21 (20.1%) 21 (20.1%) 21 (20.1%) 21 (20.1%) 21 (20.1%) 21 (20.1%) 21 (20.1%)	Salacup 2020 [36]	USA	ROS	242	66	123 (50.8%)	1 (10.070)			24 (9.9%)	
Argenziano 2020 [38]UXAROS850NR511 (60.1%)288 (33.9%)184 (78.0%)117 (13.8%)83 (35.2%)Anish 2020 [39]CanadaROS1176979 (67.5%)16 (13.7%)16 (13.7%)16 (13.7%)Aggarval 2020 [41]USAROS24266123 (50.8%)26 (10.7%)26 (10.7%)Yi 2020 [42]ChinaROS546333 (61.1%)2 (3.7%)5 (3.7%)5 (3.7%)Wan 2020 [43]ChinaROS1557772 (53.3%)5 (3.7%)10 (21.7%)1 (0.6%)Goyal 2020 [45]USAROS1555110 (66.7%)6 (40.0%)2 (13.3%)5 (3.7%)Goyal 2020 [46]USAROS1555110 (66.7%)6 (40.0%)2 (13.3%)5 (21.3%)Crespo 2020 [47]SpainROS15573.611 (73.3%)5 (33.3%)5 (71.4%)3 (20.0%)Crespo 2020 [49]12 centersROS1446294 (65.3%)74 (52.1%)26 (59.1%)4 (20.0%)Cravedi 2020 [49]12 centersROS1446294 (65.3%)74 (52.1%)26 (59.1%)4 (20.0%)Mair 2020 [51]USAROS286022 (78.6%)6 (21.4%)13 (13.0%)3 (25.0%)Mair 2020 [52]USAROS1935795 (49.2%)5 (28.5%)7 (3.6%)10 (14.1%)Mair 2020 [54]ChinaROS755234 (44.2%)2 (2.6%)7 (3.6%)10 (14.1%) <td< td=""><td>Piva 2020 [37]</td><td>Italy</td><td>POS</td><td>33</td><td>64</td><td>30 (90.9%)</td><td></td><td></td><td></td><td>1 (3.4%)</td><td>1 (3.4%)</td></td<>	Piva 2020 [37]	Italy	POS	33	64	30 (90.9%)				1 (3.4%)	1 (3.4%)
	Argenziano 2020 [38]	USA	ROS	850	NR	511 (60.1%)	288 (33.9%)	184 (78.0%)		117 (13.8%)	83 (35.2%)
Aggarwal 2020 [40]IndiaROS3254.519 (59.4%)13 (40.6%)12 (10.7%)10 (10.7%)Haydar 2020 [41]USAROS24266123 (50.8%)2 (3.7%)26 (10.7%)Vi 2020 [42]ChinaROS1354772 (53.3%)5 (3.7%)5 (3.7%)5 (3.7%)Nowak 2020 [43]ChinaROS16963.787 (51.5%)17 (10.1%)10 (21.7%)1 (0.6%)Goyal 2020 [45]USAROS37562.2238 (63.5%)18 (4.8%)18 (4.8%)Hardy 2020 [46]USAROS155110 (66.7%)6 (40.0%)5 (71.4%)3 (20.0%)Grobia 2020 [46]USAROS1573.611 (73.3%)5 (33.3%)5 (71.4%)3 (20.0%)Grobia 2020 [46]U2AROS1446294 (65.3%)74 (52.1%)26 (59.1%)4Husain-Syed 2020 [50]GermanyPOS236019 (82.6%)10 (83.3%)3 (13.0%)3 (25.0%)Marg 2020 [51]USAROS10576 (60.0%)5 (50.0%)6 (21.4%)4Mang 2020 [51]USAROS10575 (28.6%)7 (3.6%)4Marg 2020 [53]ChinaROS19464179 (52.0%)80 (60.2%)9 (2.6%)4Li 2020 [54]TurkeyROS4044.920 (50%)3 (7.5%)7 (3.6%)7 (3.6%)Jiang 2020 [55]ChinaROS193575 (28.6%)7 (3.6%) <t< td=""><td>Anish 2020 [39]</td><td>Canada</td><td>ROS</td><td>117</td><td>69</td><td>79 (67.5%)</td><td>,</td><td></td><td></td><td>16 (13.7%)</td><td>16 (13.7%)</td></t<>	Anish 2020 [39]	Canada	ROS	117	69	79 (67.5%)	,			16 (13.7%)	16 (13.7%)
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Aggarwal 2020 [40]	India	ROS	32	54.5	19 (59.4%)	13 (40.6%)				
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Haydar 2020 [41]	USA	ROS	242	66	123 (50.8%)	. ,			26 (10.7%)	
$ \begin{array}{ c c c c c c } Wan 2020 [43] & China & ROS & 135 & 47 & 72 (53.3%) & 5 (3.7\%) & & 5 (3.7\%) & & 5 (3.7\%) \\ \hline Nowak 2020 [44] & Polan & ROS & 169 & 63.7 & 87 (51.5\%) & 17 (10.1%) & 10 (21.7\%) & 10 (0.5\%) \\ \hline Copyal 2020 [45] & USA & ROS & ROS & 375 & 62.2 & 238 (63.5\%) & & 2 (13.3\%) & 5 (71.4\%) & 3 (20.0\%) \\ \hline Hardy 2020 [46] & USA & ROS & 15 & 73.6 & 1106 (67.3\%) & 6 (40.0\%) & 120 (26.1\%) & 120 (26.1\%) \\ \hline Crespo 2020 [47] & Spain & ROS & 2226 & 61 & 1074 (48.2\%) & 173 (7.8\%) & 26 (59.1\%) & & \\ \hline Cravedi 2020 [49] & 12 centers & ROS & 144 & 62 & 94 (65.3\%) & 74 (52.1\%) & 26 (59.1\%) & \\ \hline Husain-Syed 2020 [50] & Germany & POS & 23 & 60 & 19 (82.6\%) & 74 (52.9\%) & 10 (83.3\%) & & 3 (3.0\%) & 3 (25.0\%) \\ \hline Adain 2020 [51] & USA & ROS & 144 & 62 & 94 (65.3\%) & 5 (50.0\%) & & & \\ \hline Adain 2020 [52] & USA & ROS & 28 & 60 & 22 (78.6\%) & & & 6 (21.4\%) & \\ \hline Adain 2020 [52] & USA & ROS & 28 & 60 & 22 (78.6\%) & & & & 6 (21.4\%) & \\ \hline Adain 2020 [53] & China & ROS & 344 & 64 & 179 (52.0\%) & 8 (62.5.0\%) & & & & & & 6 (21.4\%) & \\ \hline Adain 2020 [54] & Turkey & ROS & 193 & 57 & 95 (49.2\%) & 55 (28.5\%) & & & & & & & & & & & \\ \hline Adaa 2020 [55] & China & ROS & 77 & 52 & 34 (44.2\%) & 2 (2.6\%) & & & & & & & & & & & & & & & \\ \hline Adaa 2020 [55] & China & ROS & 77 & 52 & 34 (44.2\%) & 2 (2.6\%) & & & & & & & & & & & & & & & & & & \\ \hline Adaa 2020 [55] & China & ROS & 77 & 52 & 34 (44.2\%) & 2 (2.6\%) & & & & & & & & & & & & & & & & & & &$	Yi 2020 [42]	China	ROS	54	63	33 (61.1%)	2 (3.7%)			. ,	
$ \begin{array}{ c c c c c c c c c c c c c c c c c c c$	Wan 2020 [43]	China	ROS	135	47	72 (53.3%)	5 (3.7%)			5 (3.7%)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Nowak 2020 [44]	Poland	ROS	169	63.7	87 (51.5%)	17 (10.1%)		10 (21.7%)	1 (0.6%)	
Hardy 2020 [46]USAROS155110 (66.7%) 6 (40.0%) (213.3%) 2 (13.3%) (13.3%) (13.3%) (13.3%) (213.3%) $(2$	Goyal 2020 [45]	USA	ROS	375	62.2	238 (63.5%)				18 (4.8%)	
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	Hardy 2020 [46]	USA	ROS	15	51	10 (66.7%)	6 (40.0%)			2 (13.3%)	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $	Crespo 2020 [47]	Spain	ROS	15	73.6	11 (73.3%)	5 (33.3%)		5 (71.4%)	3 (20.0%)	
Cravedi 2020 [49]12 centersROS1446294 (65.3%)74 (52.1%)26 (59.1%)Husain-Syed 2020 [50]GermanyPOS236019 (82.6%)12 (52.2%)10 (83.3%)3 (13.0%)3 (25.0%)Nair 2020 [51]USAROS10576 (60.0%)5 (50.0%)6 (21.4%)6 (21.4%)6 (21.4%)Wang 2020 [53]ChinaROS34464179 (52.0%)86 (25.0%)80 (60.2%)9 (2.6%)-Demir 2020 [54]TurkeyROS4044.920 (50%)3 (7.5%)7 (3.6%)Li 2020 [8]ChinaROS1935795 (49.2%)55 (28.5%)-7 (3.6%)Zhao 2020 [55]ChinaROS1935795 (49.2%)55 (19.2%)3 (5.5%)<	Borobia 2020 [48]	Spain	ROS	2226	61	1074 (48.2%)	173 (7.8%)		120 (26.1%)		
Husain-Syed 2020 [50]GermanyPOS236019 (82.6%)12 (52.2%)10 (83.3%)3 (13.0%)3 (25.0%)Nair 2020 [51]USAROS10576 (60.0%)5 (50.0%)6 (21.4%)6 (21.4%)Akalin 2020 [52]USAROS286022 (78.6%)80 (60.2%)9 (2.6%)6 (21.4%)Wang 2020 [53]ChinaROS34464179 (52.0%)86 (25.0%)80 (60.2%)9 (2.6%)10Demir 2020 [54]TurkeyROS4044.920 (50%)3 (7.5%)7 (3.6%)7 (3.6%)10Li 2020 [8]ChinaROS1935795 (49.2%)55 (28.5%)7 (3.6%)7 (3.6%)10Zhao 2020 [55]ChinaROS775234 (4.2%)2 (2.6%)101014.1%)Jiang 2020 [57]ChinaROS554527 (55.7%)3 (5.5%)5 (14.7%)10 (14.1%)10 (14.1%)Zheng 2020 [58]ChinaROS346623 (67.6%)7 (20.6%)5 (14.7%)10 (14.1%)10 (14.1%)Almin 2020 [59]FranceROS1064388 (81.0%)14 (1.3%)5 (0.5%)10 (2.2%)9 (13.6%)Yang 2020 [61]ChinaROS1035388 (85.4%)10 (2.2%)9 (13.6%)10 (2.2%)9 (13.6%)Aleidan 2020 [62]KuwaitROS1035388 (85.4%)10 (2.2%)9 (13.6%)10 (2.2%)9 (13.6%)Yang 2020 [61]China	Cravedi 2020 [49]	12 centers	ROS	144	62	94 (65.3%)	74 (52.1%)		26 (59.1%)		
Nair 2020 [51]USAROS10576 (60.0%)5 (50.0%)Akalin 2020 [52]USAROS286022 (78.6%)6 (21.4%)Wang 2020 [53]ChinaROS34464179 (52.0%)86 (25.0%)80 (60.2%)9 (2.6%)Demir 2020 [54]TurkeyROS4044.920 (50%)3 (7.5%)7 (3.6%)7 (3.6%)Zhao 2020 [55]ChinaROS1935795 (49.2%)55 (28.5%)7 (3.6%)7 (3.6%)Zhao 2020 [56]ChinaROS28762160 (55.7%)55 (19.2%)7 (3.6%)10 (14.1%)Jiang 2020 [57]ChinaROS554527 (55.7%)3 (5.5%)5 (14.7%)Zheng 2020 [58]ChinaROS346623 (67.6%)7 (20.6%)5 (14.7%)Rubin 2020 [59]FranceROS7161.255 (77.5%)57 (80.3%)57 (80.3%)5 (14.7%)Almazeedi 2020 [60]KuwaitROS109641888 (81.0%)14 (1.3%)10 (14.1%)10 (14.1%)Almazeedi 2020 [61]ChinaROS1035388 (85.4%)21 (20.4%)21 (20.4%)21 (20.4%)Gaetano 2020 [63]ItalyROS30765.2219 (71.3%)69 (22.4%)24 (39.3%)5 (1.6%)Shi 2020 [64]ChinaROS333388 (85.4%)1 (0.7%)1 (0.7%)China 2020 [64]ItalyROS30765.2219 (71.3%)69 (22.4%)24 (39.3%) <td< td=""><td>Husain-Syed 2020 [50]</td><td>Germany</td><td>POS</td><td>23</td><td>60</td><td>19 (82.6%)</td><td>12 (52.2%)</td><td>10 (83.3%)</td><td></td><td>3 (13.0%)</td><td>3 (25.0%)</td></td<>	Husain-Syed 2020 [50]	Germany	POS	23	60	19 (82.6%)	12 (52.2%)	10 (83.3%)		3 (13.0%)	3 (25.0%)
Akalin 2020 [52]USAROS2860 $22 (78.6\%)$ $6 (21.4\%)$ Wang 2020 [53]ChinaROS34464179 (52.0\%)86 (25.0%)80 (60.2%)9 (2.6%)Demir 2020 [54]TurkeyROS4044.920 (50%)3 (7.5%)7 (3.6%)1Li 2020 [8]ChinaROS1935795 (49.2%)55 (28.5%)7 (3.6%)7 (3.6%)Zhao 2020 [55]ChinaROS775234 (44.2%)2 (2.6%)7 (3.6%)1Xiao 2020 [56]ChinaROS28762160 (55.7%)55 (19.2%)55 (19.2%)11Jiang 2020 [57]ChinaROS346623 (67.6%)7 (20.6%)5 (14.7%)10 (14.1%)Zheng 2020 [58]ChinaROS346623 (67.6%)7 (20.6%)57 (80.3%)57 (80.3%)10 (14.1%)Almazeedi 2020 [60]KuwaitROS109641888 (81.0%)14 (1.3%)10 (14.1%)10 (14.1%)Almazeedi 2020 [61]ChinaROS1035388 (85.4%)21 (20.4%)21 (20.4%)21 (20.4%)Ayed 2020 [62]KuwaitROS1035388 (85.4%)21 (20.4%)5 (1.6%)21 (20.4%)21 (20.4%)Gaetano 2020 [63]ItalyROS30765.2219 (71.3%)69 (22.4%)24 (39.3%)5 (1.6%)10 (0.7%)Shi 2020 [64]ChinaROS1344669 (51.5%)3 (2.2%)14 (3.9%)5 (1.6%)10	Nair 2020 [51]	USA	ROS	10	57	6 (60.0%)	5 (50.0%)				
Wang 2020 [53]ChinaROS34464179 (52.0%)86 (25.0%)80 (60.2%)9 (2.6%)Demir 2020 [54]TurkeyROS4044.920 (50%)3 (7.5%)777 <td>Akalin 2020 [52]</td> <td>USA</td> <td>ROS</td> <td>28</td> <td>60</td> <td>22 (78.6%)</td> <td></td> <td></td> <td></td> <td>6 (21.4%)</td> <td></td>	Akalin 2020 [52]	USA	ROS	28	60	22 (78.6%)				6 (21.4%)	
	Wang 2020 [53]	China	ROS	344	64	179 (52.0%)	86 (25.0%)		80 (60.2%)	9 (2.6%)	
Li 2020 [8] China ROS 193 57 95 (49.2%) 55 (28.5%) 7 (3.6%) Zhao 2020 [55] China ROS 77 52 34 (44.2%) 2 (2.6%) Xiao 2020 [56] China ROS 287 62 160 (55.7%) 55 (19.2%) Jiang 2020 [57] China ROS 34 66 23 (67.6%) 7 (20.6%) 5 (14.7%) Rubin 2020 [59] France ROS 71 61.2 55 (77.5%) 57 (80.3%) 57 (80.3%) 10 (14.1%) 10 (14.1%) Almazeedi 2020 [60] Kuwait ROS 1096 41 888 (81.0%) 14 (1.3%) 5 (0.5%) Yang 2020 [61] China ROS 463 60 231 (49.9%) 35 (7.6%) 19 (28.8%) 10 (2,2%) 9 (13.6%) Ayed 2020 [62] Kuwait ROS 103 53 88 (85.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%)<	Demir 2020 [54]	Turkey	ROS	40	44.9	20 (50%)	3 (7.5%)			- (2, (2))	
Zhao 2020 [55]ChinaROS775234 (44.2%)2 (2.6%)Xiao 2020 [56]ChinaROS28762160 (55.7%)55 (19.2%)Jiang 2020 [57]ChinaROS554527 (55.7%)3 (5.5%)Zheng 2020 [58]ChinaROS346623 (67.6%)7 (20.6%)57 (80.3%)Rubin 2020 [59]FranceROS7161.255 (77.5%)57 (80.3%)57 (80.3%)10 (14.1%)Almazeedi 2020 [60]KuwaitROS109641888 (81.0%)14 (1.3%)5 (0.5%)Yang 2020 [61]ChinaROS46360231 (49.9%)35 (7.6%)19 (28.8%)10 (2,2%)9 (13.6%)Ayed 2020 [62]KuwaitROS1035388 (85.4%)21 (20.4%)21 (20.4%)21 (20.4%)21 (20.4%)Gaetano 2020 [63]ItalyROS30765.2219 (71.3%)69 (22.4%)24 (39.3%)5 (1.6%)Shi 2020 [64]ChinaROS1344669 (51.5%)3 (2.2%)1 (0.7%)10 (7.5%)Lubetzky 2020 [65]USAROS395931 (79.5%)20 (51.3%)50 (12.8%)50 (12.8%)Lubetzky 2020 [65]USAROS323566 51868 (57.7%)1406(43.5%)280 (68 %)	Li 2020 [8]	China	ROS	193	57	95 (49.2%)	55 (28.5%)			7 (3.6%)	
Xiao 2020 [56] China ROS 287 62 160 (55.7%) 55 (19.2%) Jiang 2020 [57] China ROS 55 45 27 (55.7%) 3 (5.5%) Zheng 2020 [58] China ROS 34 66 23 (67.6%) 7 (20.6%) 57 (80.3%) 57 (80.3%) 10 (14.1%) 10 (14.1%) Almazedi 2020 [60] Kuwait ROS 1096 41 888 (81.0%) 14 (1.3%) 50.5% Yang 2020 [61] China ROS 463 60 231 (49.9%) 35 (7.6%) 19 (28.8%) 10 (2.2%) 9 (13.6%) Ayed 2020 [62] Kuwait ROS 103 53 88 (85.4%) 24 (39.3%) 51 (1.6%) 21 (20.4%) 21 (Zhao 2020 [55]	China	ROS	77	52	34 (44.2%)	2 (2.6%)				
Jahag 2020 [57] China ROS 55 45 27 (55.7%) 3 (5.5%) Zheng 2020 [58] China ROS 34 66 23 (67.6%) 7 (20.6%) 5 (14.7%) Rubin 2020 [59] France ROS 71 61.2 55 (77.5%) 57 (80.3%) 57 (80.3%) 10 (14.1%) 10 (14.1%) Almazeedi 2020 [60] Kuwait ROS 1096 41 888 (81.0%) 14 (1.3%) 5 (0.5%) Yang 2020 [61] China ROS 463 60 231 (49.9%) 35 (7.6%) 19 (28.8%) 10 (2,2%) 9 (13.6%) Ayed 2020 [62] Kuwait ROS 103 53 88 (85.4%) 21 (20.4%) 2	Xiao 2020 [56]	China	ROS	287	62	160 (55.7%)	55 (19.2%)				
Zneng 2020 [55]ChinaROS346623 (67.5%) $7 (20.5\%)$ $57 (80.3\%)$ $51 (14.7\%)$ Rubin 2020 [59]FranceROS7161.2 $55 (77.5\%)$ $57 (80.3\%)$ $57 (80.3\%)$ $10 (14.1\%)$ $10 (14.1\%)$ Almazeedi 2020 [60]KuwaitROS109641888 (81.0\%) $14 (1.3\%)$ $5 (0.5\%)$ Yang 2020 [61]ChinaROS46360231 (49.9%) $35 (7.6\%)$ $19 (28.8\%)$ $10 (2,2\%)$ $9 (13.6\%)$ Ayed 2020 [62]KuwaitROS103 53 88 (85.4%) $21 (20.4\%)$ $21 (20.4\%)$ $21 (20.4\%)$ $21 (20.4\%)$ Gaetano 2020 [63]ItalyROS307 65.2 $219 (71.3\%)$ $69 (22.4\%)$ $24 (39.3\%)$ $5 (1.6\%)$ Shi 2020 [64]ChinaROS13446 $69 (51.5\%)$ $3 (2.2\%)$ $1 (0.7\%)$ Lubetzky 2020 [65]USAROS39 59 $31 (79.5\%)$ $20 (51.3\%)$ $5 (12.8\%)$ Lubetzky 2020 [65]USAROS $323 5 66 5$ $1868 (57.7\%)$ $1406(43.5\%)$ $280 (8.6\%)$	Jiang 2020 [57]	China	ROS	55	45	27 (55.7%)	3 (5.5%)			F (1 4 70/)	
Rubni 2020 [65] France ROS 7.1 61.2 55 (77.5%) 57 (80.5%) 57 (80.5%) 10 (14.1%) 10 (14.1%) Almazeedi 2020 [60] Kuwait ROS 1096 41 888 (81.0%) 14 (1.3%) 50 (0.5%) 50 (0.5%) Yang 2020 [61] China ROS 463 60 231 (49.9%) 35 (7.6%) 19 (28.8%) 10 (2,2%) 9 (13.6%) Ayed 2020 [62] Kuwait ROS 103 53 88 (85.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) Gaetano 2020 [63] Italy ROS 307 65.2 219 (71.3%) 69 (22.4%) 24 (39.3%) 5 (1.6%) Shi 2020 [64] China ROS 134 46 69 (51.5%) 3 (2.2%) 1 (0.7%) Lubetzky 2020 [65] USA ROS 39 59 31 (79.5%) 20 (51.3%) 5 (12.8%) Chan 2020 [66] USA ROS 323 (65.5 1868 (57.7%) 1406(43.5%) 280 (8.6%)	Zitelig 2020 [56]	Cililia	ROS	34	61.0	23 (07.0%)	7 (20.0%)	F7 (00 20/)		5(14.7%)	10 (14 10/)
Annazzetu 2020 [60] Kuwali KOS 1000 41 0000 14 (1.5%) 14 (1.5%) 16 (1.5%) 10 (2,2%) 9 (13.6%) Yang 2020 [61] China ROS 463 60 231 (49.9%) 35 (7.6%) 19 (28.8%) 10 (2,2%) 9 (13.6%) Ayed 2020 [62] Kuwait ROS 103 53 88 (85.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) Gaetano 2020 [63] Italy ROS 307 65.2 219 (71.3%) 69 (22.4%) 24 (39.3%) 5 (1.6%) Shi 2020 [64] China ROS 134 46 69 (51.5%) 3 (2.2%) 10 (7.7%) 10 (7.7%) Lubetzky 2020 [65] USA ROS 39 59 31 (79.5%) 20 (51.3%) 5 (12.8%) 5 (12.8%) Chan 2020 [66] USA ROS 323 (65.5 1868 (57.7%) 1406(43.5%) 280 (68.6%) 280 (68.6%)	Almarcodi 2020 [59]	France	RUS	/1	01.2	55 (77.5%) 999 (91.004)	57 (80.3%) 14 (1.204)	57 (80.3%)		10(14.1%)	10 (14.1%)
Aig 2020 [61] China ROS 405 60 201 (42.5%) 55 (7.6%) 19 (25.6%) 10 (2,2%) 9 (15.6%) Ayed 2020 [62] Kuwait ROS 103 53 88 (85.4%) 21 (20.4%) 21 (20.4%) 21 (20.4%) Gaetano 2020 [63] Italy ROS 307 65.2 219 (71.3%) 69 (22.4%) 24 (39.3%) 5 (1.6%) Shi 2020 [64] China ROS 134 46 69 (51.5%) 3 (2.2%) 1 (0.7%) Lubetzky 2020 [65] USA ROS 39 59 31 (79.5%) 20 (51.3%) 5 (12.8%) Chan 2020 [66] USA ROS 3235 66 5 1868 (57.7%) 1406(43.5%) 280 (8.6%)	Xang 2020 [61]	China	ROS	1090	41 60	221 (40.0%)	14 (1.3%) 35 (7.6%)	10 (28 8%)		3 (0.3%) 10 (2.2%)	0 (13 6%)
Agree 2020 [62] Kathat ROS 105 55 05 (05,7%) 21 (20,4	Aved 2020 [62]	Kuwait	ROS	103	53	88 (85.4%)	33 (7.070)	17 (20.070)		21 (20.4%)	21 (20.4%)
Shi 2020 [64] China ROS 134 46 69 (51.5%) 3 (2.2%) 1 (0.7%) Lubetzky 2020 [65] USA ROS 39 59 31 (79.5%) 20 (51.3%) 5 (12.8%) Chan 2020 [66] USA ROS 3235 66 5 1866 (57.7%) 1406(43.5%) 280 (6.6%)	Gaetano 2020 [63]	Italy	ROS	307	65.2	219 (71 3%)	69 (22.4%)	24 (39 3%)		5(1.6%)	21 (20.7/0)
Lubetzky 2020 [65] USA ROS 39 59 31 (79.5%) 20 (51.3%) 5 (12.8%) Chan 2020 [66] USA ROS 395 56 1866 (75.7%) 1406(43.5%) 280 (8.6%)	Shi 2020 [64]	China	ROS	134	46	69 (51.5%)	3 (2.2%)	- (0).0,0)		1 (0.7%)	
Chan 2020 [66] UISA BOS 3235 66 5 1868 (57.7%) 1406(43.5%) 280 (8.6%)	Lubetzky 2020 [65]	USA	ROS	39	59	31 (79.5%)	20 (51.3%)			5 (12.8%)	
	Chan 2020 [66]	USA	ROS	3235	66.5	1868 (57.7%)	1406(43.5%)			280 (8.6%)	
Poneprirul 2020 [67] Thailand ROS 193 37 113 (58.5%) 7 (6.3%) 5 (83.3%)	Pongpirul 2020 [67]	Thailand	ROS	193	37	113 (58.5%)	7 (6.3%)	5 (83.3%)			
Xu 2020 [68] China ROS 45 56.7 29 (64.4%) 7 (15.6%) 4 (8.9%)	Xu 2020 [68]	China	ROS	45	56.7	29 (64.4%)	7 (15.6%)	. ()		4 (8.9%)	
Yan 2020 [69] China ROS 168 51 81 (48.2%) 6 (3.6%)	Yan 2020 [69]	China	ROS	168	51	81 (48.2%)	6 (3.6%)				

ROS: retrospective observational study; POS: prospective observational study; AKI: acute kidney injury; RRT: renal replacement therapy; ICU: intensive care unit;

search terms: "COVID-19", "2019-nCoV", "SARA-CoV-2", "novel coronavirus" "Acute Kidney Injury", and "Acute Renal Failure". The search strategy was presented in Online Appendix 1. COVID-19-related reports in relevant literature reviews and the references of included studies were also searched to identify other relevant analyses.

2.2. Study selection

Studies eligible for inclusion in this meta-analysis were: (1) observational studies reporting rates of AKI and RRT use in COVID-19 patients; (2) published studies that met with relevant requirements, regardless of whether or not AKI definition was mentioned; and (3) pre-

print articles that included an explicit definition of AKI.

Studies were excluded from this analysis if they were abstracts, editorials, reviews, letters, conference abstracts, or commentaries. For any studies reporting on patient populations within the same hospital during overlapping time periods, only the study with the most comprehensive dataset was included in this analysis.

2.3. Data extraction

Two investigators (XPY and SST) independently reviewed studies, extracted data, and assessed study quality. Any discrepancies were resolved by a third investigator (HG).

Table 2

Newcastle-Ottawa score of the included studies.

Study	Exposed cohortepresentative	Non exposed cohort selected from same source	Exposure ascertained	Outcome of study was not present at start of the study	Comparability	Adequate assessment	Follow up was long enough	Adequate follow-up	Quality score
Wang 2020	*	*	*		*	*	*	*	*****
Wang 2020	*	*	*	*	*	*	*	*	*******
Richardson	*	*	*		*	*	*	*	******
2020									
Huang 2020	*	*	*		*	*	*	*	******
Cheng 2020	*	*	*	×	*	*	*	*	******
Gilan 2020	*		*		*	*	*	*	*****
Alberici	*		*			*	*	*	****
2020									
Yang 2020	*	*	*		*	*	*	*	******
Zhou 2020	*	*	*		*	*	*	*	*****
Chen 2020	*		*			*	*	*	****
Arentz 2020	*		*			*	*	*	****
Banerjee	×		*				*	*	****
2020 Dong 2020	*	*	*		*		*	*	*****
Guo 2020	*		*				*	*	****
Lei 2020	*	*	*		*	*	*	*	*****
Shi 2020	*		*			*	*	*	*****
Wang 2020	*	*	*		*	*	*	*	******
Zhang 2020	*		*		*	**	*	*	*****
Zhang 2020	*		*		*		*	*	****
Hu 2020	*	*	*		*		*	*	*****
Brill 2020	*	*	**		*	*	*	*	******
Cheung 2020	*	*	*		*	*	**	*	*****
2020									
Piva 2020	*		*	*			*	*	****
Argenziano	*	*	*		*	*	*	*	******
2020									
Anish 2020	*		*				*	*	****
Aggarwal	*		**		*	*	*	*	*****
2020									
Haydar 2020	*		*				*	*	****
Y1 2020	*		*		*	*	*	*	*****
Wan 2020	*	*	*		**	*	*	*	******
Goval 2020	*	*	*		**		*	*	*****
Hardy 2020	*		*				*	*	****
Crespo 2020	*	*	*		*		*	*	*****
Borobia	*	*	*		*	*	*	*	******
2020									
Cravedi 2020	*	*	*		*	*	*	*	*****
Husain-Syed	*	*	*	*	*	*	*	*	*******
2020 Nair 2020	*		*			*	*	*	****
Akalin 2020	*		*				*	*	****
Wang 2020	*	*	*		*	**	*	*	*****
Demir 2020	*		*			*	*	*	****
Li 2020	*		*		*	*	*	*	*****
Zhao 2020	*		*		*	*	*	*	****
Xiao 2020	*		*			*	*	*	****
Jiang 2020	*	*	*		*	*	*	*	*****
Zheng 2020	*	2	*	*	*	*	*	*	******
Almazeedi	*		*			*	*	*	****
2020									
Yang 2020	*	*	*		*	*	*	*	******
Ayed 2020	*		*			*	*	*	***
Gaetano	*	*	*		*	*	*	*	******
2020									
Shi 2020	*		*		*	**	*	*	*****
Lubetzky	*		*		*	*	*	*	*****
2020									
Chan 2020	*	*	*		**	*	*	*	******
2020									
Xu 2020	*	*	*		*	*	*	*	******
Yan 2020	*		*		*	*	*	*	*****

Study	Events	Total	Proportion	95%-Cl Weight
Wang 2020	5	138 🛨 :	0.036 [0.0	12: 0.083] 1.9%
Wang 2020	0	116 🖷	0.01 000.0	00:0.0311 0.7%
Richardson 2020	1370	5700 +	0.240 [0.2	29: 0.2521 2.4%
Huang 2020	3	41	0.073 [0.0	15; 0.199] 1.7%
Cheng 2020	36	701 😐	0.051 [0.03	36; 0.070] 2.3%
Chen 2020	29	274 +	0.106 [0.0	72; 0.148] 2.3%
Guan 2020	6	1099	0.005 [0.0	02; 0.012] 2.0%
Alberici 2020	6	20	0.300 [0.1	19; 0.543] 1.9%
Yang 2020	15	52	0.288 [0.1]	71; 0.431] 2.1%
Zhou 2020	28	191 🕂	0.147 [0.1	00; 0.205] 2.2%
Chen 2020	3	99 🛨	0.030 [0.0	06; 0.086] 1.7%
Arentz 2020	4	21	0.190 [0.0	54; 0.419] 1.7%
Benerjee 2020	4	7	0.571 [0.1	84; 0.901] 1.4%
Deng 2020	20	225 +	0.089 [0.0	55; 0.134] 2.2%
Guo 2020	18	187 🛨	0.096 [0.0	58; 0.148] 2.2%
Lei 2020	2	34	0.059 [0.0	07; 0.197] 1.5%
Shi 2020	8	416	0.019 [0.0	08; 0.038] 2.1%
Wang 2020	14	107	0.131 [0.0	73; 0.210] 2.2%
Zhang 2020	10	221 🛨	0.045 [0.02	22; 0.082] 2.1%
Zhang 2020	2	645	0.003 [0.0	00; 0.011] 1.5%
Hu 2020	17	323	0.053 [0.03	31; 0.083] 2.2%
Brill 2020	85	450	0.189 [0.1	54; 0.228] 2.3%
Cheung 2020	1	10	0.100 [0.0	03; 0.445] 1.0%
Argenziano 2020	288	850	0.339 [0.3	07; 0.372] 2.3%
Aggarwal 2020	13	32	0.406 [0.2	37; 0.594] 2.1%
YI 2020	2	54	0.037 [0.0	05,0.127] 1.5%
Wan 2020 Newsk 2020	17	135 - :	0.037 [0.0	12,0.084] 1.9%
NOWak 2020	6	15	0.101 [0.0	00,0.100] 2.2% 62:0.6771 1.00/
	5	15	0.400 [0.1	10.06161 1.0%
Borobia 2020	172	2226 +	0.333 [0.1	67·0.0001 2.2%
Cravedi 2020	74	144	0.514 [0.4	20.05081 2.3%
Husain-Sved 2020	12	23	0.522 [0.3]	06:07321 2.0%
Nair 2020	5	10	0.500 [0.1	87 0 8131 1 6%
Wang 2020	86	344	0 250 [0 2	05 0 2991 2 3%
Demir 2020	3	40	0.075 [0.0	16: 0.204] 1.7%
Li 2020	55	193	0.285 [0.2	22: 0.3541 2.3%
Zhao 2020	2	77 =	0.026 [0.0	03: 0.0911 1.5%
Xiao 2020	55	287	0.192 [0.1	48: 0.242] 2.3%
Jiang 2020	3	55 ++	0.055 0.0	11: 0.151 1.7%
Zheng 2020	7	34 +	0.206 [0.0	87; 0.379] 2.0%
Rubin 2020	57	71	0.803 [0.6	91; 0.888] 2.1%
Almazeedi 2020	14	1096 •	0.013 [0.0	07; 0.021] 2.2%
Yang 2020	35	463	0.076 [0.0	53; 0.104] 2.3%
Gaetano 2020	69	307 +	0.225 [0.1]	79; 0.276] 2.3%
Shi 2020	3	134 🛨	0.022 [0.0	05; 0.064] 1.7%
Lubetzky 2020	20	39	0.513 [0.34	48; 0.676] 2.1%
Chan 2020	1406	3235 *	0.435 [0.4	17; 0.452] 2.4%
Pongpirul 2020	7	193 🛨 🔄	0.036 [0.0	15; 0.073] 2.0%
Xu 2020	7	45	0.156 [0.0	65; 0.295] 2.0%
Yan 2020	6	168 🎹	0.036 [0.0	13; 0.076] 2.0%
Dandam offersterne de		24524	0 400 10 0	DE. 0 4EC1 400 00
Random effects mode	2 0 070 /		U.123 [0.09	95; 0.156] 100.0%
Heterogeneity: /- = 9/%, τ	= 0.8794	, p = 0	4	
		0 0.2 0.4 0.0 0.8	1	

Fig. 2a. Forest plot depicting the incidence of AKI in COVID-19 patients.

Data extracted from each study included study design, study title, first author, year of publication, country, patient information, AKI incidence, and rates of RRT use.

19 patients, among COVID-19 patients admitted to the intensive care unit (ICU), and among deceased COVID-19 patients. Secondary outcomes included RRT use in total COVID-19 patients and among COVID-19 patients admitted to the ICU.

Observational study quality was evaluated using the Newcastle-Ottawa Scale.

Primary study outcomes included AKI incidence among total COVID-

Study	Events	Total	Proportion	95%-Cl Weight			
subgroup = non-kidney Wang 2020 Wang 2020 Richardson 2020 Huang 2020 Cheng 2020 Cheng 2020	transpla 5 0 1370 3 36 29	ant recipients 138 ↔ 116 ↔ 5700 ↔ 41 ↔ 701 ↔ 274 ↔	0.036 [0.0 0.000 [0.00 0.240 [0.22 0.073 [0.0 0.051 [0.03 0.106 [0.03	12; 0.083] 1.9% 00; 0.031] 0.7% 29; 0.252] 2.4% 15; 0.199] 1.7% 36; 0.070] 2.3% 72 0 148] 2.3%			
Guan 2020	6 15	1099	0.005 [0.00)2; 0.012] 2.0%			
Zhou 2020	28	191	0.147 [0.10	0, 0.205] 2.2%			
Arentz 2020	3	21	0.030 [0.00	54; 0.419] 1.7%			
Deng 2020 Guo 2020	20 18	225 +	0.089 [0.05	55; 0.134] 2.2%			
Lei 2020	2	34	0.059 [0.00	07; 0.197] 1.5%			
Shi 2020 Wang 2020	8 14	416	0.019 [0.00 0.131 [0.07)8; 0.038] 2.1% 73: 0.210] 2.2%			
Zhang 2020	10	221 +	0.045 [0.02	22; 0.082] 2.1%			
Hu 2020	17	323	0.053 [0.03	31; 0.083] 2.2%			
Brill 2020 Cheung 2020	85 1	450 +	0.189 [0.15 0.100 [0.00	54; 0.228] 2.3%			
Argenziano 2020	288	850	0.339 [0.30	07; 0.372] 2.3%			
Aggarwai 2020 Yi 2020	13	32	0.406 [0.23	0.5; 0.127] 1.5%			
Wan 2020 Nowak 2020	5 17	135 + 1	0.037 [0.01	12; 0.084] 1.9%			
Borobia 2020	173	2226	0.078 [0.06	57; 0.090] 2.3%			
Husain-Syed 2020 Wang 2020	12 86	344	0.522 [0.30 0.250 [0.20	06; 0.732] 2.0% 05; 0.299] 2.3%			
Li 2020	55	193	0.285 [0.22	22; 0.354] 2.3%			
Xiao 2020	55	287 +	0.192 [0.14	48; 0.242] 2.3%			
Jiang 2020 Zheng 2020	3 7	55 - : 34 - :	0.055 [0.0 ⁴ 0.206 [0.08	11; 0.151] 1.7% 37: 0.379] 2.0%			
Rubin 2020	57	71	0.803 [0.69	91; 0.888] 2.1%			
Yang 2020	35	463	0.013 [0.03	53; 0.104] 2.3%			
Gaetano 2020 Shi 2020	69 3	307	0.225 [0.17	79; 0.276] 2.3%			
Chan 2020	1406	3235 +	0.435 [0.4]	17; 0.452] 2.4%			
Pongpirul 2020 Xu 2020	7	193 + : 45	0.036 [0.04	15; 0.073] 2.0% 35; 0.295] 2.0%			
Yan 2020 Pandom offects model	6	168 🛨	0.036 [0.0	13; 0.076] 2.0%			
Heterogeneity: $I^2 = 98\%$, τ	² = 0.8808,	p = 0	0.056 [0.07	4,0.129] 05.5%			
subgroup = kidney trar	nsplant re	ecipients	0.000 10 4	10: 0 5 401 4 00/			
Benerjee 2020	6 4	7	- 0.571 [0.18	34; 0.901] 1.4%			
Hardy 2020 Crespo 2020	6 5	15	0.400 [0.16	3; 0.677] 1.8%			
Cravedi 2020	74	144	0.514 [0.42	29; 0.598] 2.3%			
Nair 2020 Demir 2020	5	10	0.500 [0.18 0.075 [0.01	37; 0.813] 1.6% 16: 0.204] 1.7%			
Lubetzky 2020	20	39	0.513 [0.34	48; 0.676] 2.1%			
Heterogeneity: $I^2 = 67\%$, τ	² = 0.3401,	, p < 0.01	0.389 [0.27	5;0.519] 14.5%			
Random effects model 21531							
Heterogeneity: $l^2 = 97\%$, $\tau^2 = 0.8794$, $\rho = 0$ Residual heterogeneity: $l^2 = 97\%$, $\rho = 0$ 0 0.2 0.4 0.6 0.8 1							



Study	Events	Total	Proportion	95%-CI Weight
subgroup = Asia Wang 2020 Wang 2020 Huang 2020 Cheng 2020 Guan 2020 Zhou 2020 Chen 2020 Chen 2020 Chen 2020 Chen 2020 Guo 2020 Lei 2020 Shi 2020 Wang 2020 Zhang 2020 Zhang 2020 Hu 2020 Aggarwal 2020 Wang 2020 Wang 2020 Uwang 2020 Li 2020 Wang 2020 Li 2020 Zhao 2020 Li 2020 Zhao 2020 Jiang 2020 Zhang 2020 Zhang 2020 Shi 2020 Yang 2020 Shi 2020 Pongpirul 2020 Xu 2020 Yan 2020	5 0 3 36 29 6 15 28 3 20 18 2 8 14 10 2 17 13 2 5 86 3 55 2 55 3 7 5 3 7 7 6	138 116 41 701 274 1099 52 191 99 225 187 34 416 107 221 645 323 32 54 135 344 40 193 77 287 55 34 40 193 77 287 55 34 403 133 45 168	0.036 [0 0.000 [0 0.073 [0 0.051 [0 0.051 [0 0.288 [0 0.147 [0 0.030 [0 0.089 [0 0.099 [0 0.059 [0 0.019 [0 0.019 [0 0.031 [0 0.045 [0 0.037 [0 0.285 [0 0.285 [0 0.285 [0 0.285 [0 0.285 [0 0.295 [0 0.295 [0 0.295 [0 0.295 [0 0.295 [0 0.295 [0 0.295 [0 0.295 [0 0.295 [0 0.296 [0 0.076 [0 0.036 [0 0.036 [0 0.036 [0	0.012; 0.083] 2.0% 0.000; 0.031] 0.7% 0.005; 0.199] 1.7% 0.036; 0.070] 2.3% 0.072; 0.148] 2.3% 0.002; 0.012] 2.0% 0.171; 0.431] 2.2% 0.006; 0.086] 1.7% 0.055; 0.134] 2.3% 0.006; 0.086] 1.7% 0.055; 0.134] 2.3% 0.006; 0.086] 1.7% 0.055; 0.134] 2.3% 0.007; 0.197] 1.5% 0.008; 0.038] 2.1% 0.007; 0.210] 2.2% 0.000; 0.011] 1.5% 0.003; 0.024] 2.3% 0.005; 0.127] 1.5% 0.012; 0.084] 2.0% 0.205; 0.299] 2.4% 0.016; 0.204] 1.7% 0.222; 0.354] 2.3% 0.003; 0.091] 1.5% 0.014; 0.242] 2.4% 0.015; 0.242] 2.4% 0.016; 0.242] 2.4% 0.016; 0.242] 2.3% 0.003;
Random effects model Heterogeneity: $l^2 = 92\%$, τ' subgroup = North Ame Richardson 2020 Arentz 2020 Cheung 2020 Argenziano 2020 Hardy 2020 Nair 2020 Lubetzky 2020 Chan 2020 Random effects model Heterogeneity: $l^2 = 98\%$, τ' subgroup = Europe	² = 0.9392 rica 1370 4 288 6 5 20 1406 ² = 0.3037	7123 ♦ p < 0.01 5700 21 10 55700 15 10 39 3235 9880 p < 0.01 20	0.069 [0 0.240 [0 0.190 [0 0.100 [0 0.339 [0 0.400 [0 0.500 [0 0.513 [0 0.435 [0 0.346 [0	0.048; 0.096] 63.3% 0.229; 0.252] 2.4% 0.054; 0.419] 1.8% 0.003; 0.445] 1.1% 0.307; 0.372] 2.4% 0.163; 0.677] 1.8% 0.187; 0.813] 1.7% 0.348; 0.676] 2.2% 0.417; 0.452] 2.4% 0.249; 0.457] 15.7%
Alberici 2020 Benerjee 2020 Brill 2020 Nowak 2020 Crespo 2020 Borobia 2020 Husain-Syed 2020 Rubin 2020 Almazeedi 2020 Gaetano 2020 Random effects model Heterogeneity: $I^2 = 97\%$, τ	6 4 85 17 5 173 12 57 14 69 2 = 1.3796	20 7 450 169 15 2226 23 71 1096 307 4384 , p < 0.01 21387 ↔	0.300 [0 0.571 [0 0.189 [0 0.101 [0 0.333 [0 0.522 [0 0.803 [0 0.013 [0 0.225 [0 0.229 [0	0.119; 0.543] 1.9% 0.184; 0.901] 1.4% 0.154; 0.228] 2.4% 0.060; 0.156] 2.2% 0.118; 0.616] 1.8% 0.067; 0.090] 2.4% 0.306; 0.732] 2.0% 0.691; 0.888] 2.2% 0.007; 0.021] 2.2% 0.179; 0.276] 2.4% 0.121; 0.389] 21.0%
Heterogeneity: l^2 = 97%, τ^2 Residual heterogeneity: l^2	² = 0.8761, = 96%, <i>p</i> <	, p = 0	1	

Fig. 2c. Subgroup analysis depicting the incidence of AKI between different continents in COVID-19 patients.

Study	Events Tot	tal	Proportion	95%-CI	Weight
Wang 2020	5 13	38 - • :-	0.036	[0.012; 0.083]	3.4%
Wang 2020	0 1	16 🖛	0.000	[0.000; 0.031]	1.3%
Huang 2020	3 4	41 —	0.073	[0.015; 0.199]	3.0%
Cheng 2020	36 70	01 🛨	0.051	[0.036; 0.070]	4.0%
Chen 2020	29 27	74	0.106	[0.072; 0.148]	4.0%
Guan 2020	6 109	99 +	0.005	[0.002; 0.012]	3.5%
Yang 2020	15 క	52	- 0.288	[0.171; 0.431]	3.8%
Zhou 2020	28 19	91	0.147	[0.100; 0.205]	4.0%
Chen 2020	3 9	99 + -	0.030	[0.006; 0.086]	3.0%
Deng 2020	20 22	25 🕂	0.089	[0.055; 0.134]	3.9%
Guo 2020	18 18	87 🕂 -	0.096	[0.058; 0.148]	3.9%
Lei 2020	2 3	34	0.059	[0.007; 0.197]	2.6%
Shi 2020	8 41	16 🛨 🔄	0.019	[0.008; 0.038]	3.7%
Wang 2020	14 10	07	0.131	[0.073; 0.210]	3.8%
Zhang 2020	10 22	21	0.045	[0.022; 0.082]	3.7%
Zhang 2020	2 64	45	0.003	[0.000; 0.011]	2.7%
Hu 2020	17 32	23	0.053	[0.031; 0.083]	3.9%
Yi 2020	2 5	54	0.037	[0.005; 0.127]	2.7%
Wan 2020	5 13	35	0.037	[0.012; 0.084]	3.4%
Wang 2020	86 34	44	0.250	[0.205; 0.299]	4.1%
Li 2020	55 19	93	0.285	[0.222; 0.354]	4.1%
Zhao 2020	2	77	0.026	[0.003; 0.091]	2.7%
Xiao 2020	55 28	87	0.192	[0.148; 0.242]	4.1%
Jiang 2020	3 5	55 — •	0.055	[0.011; 0.151]	3.0%
Zheng 2020	7 3	34	0.206	[0.087; 0.379]	3.5%
Yang 2020	35 46	63 _ +	0.076	[0.053; 0.104]	4.0%
Shi 2020	3 13	34	0.022	[0.005; 0.064]	3.0%
Xu 2020	7 4	45	0.156	[0.065; 0.295]	3.5%
Yan 2020	6 16	68 	0.036	[0.013; 0.076]	3.5%
Random effects model	[0.045; 0.092]	100.0%			
Heterogeneity: / [~] = 92%, τ	~ = 0.9069, p <	< 0.01			
		0 0.1 0.2 0.3 0.4			

Fig. 2d. Forest plot depicting the incidence of AKI in COVID-19 patients in China.

2.4. Statistical analysis

The "meta" package for R (v.4.0.2) was used to conduct the present meta-analysis when there are five or more studies reporting the same outcome with the same definition. The normality of data distributions was assessed, and data were used in their raw form when normally distributed, whereas they were otherwise subjected to Logit transformation. Freeman-Tukey Double arcsine transformation was conducted for variables for which many values were either 0 or 1 in order to facilitate variance stabilization. A continuous correction of 0.5 was used for studies with rates of 0. Corresponding 95% confidence intervals (CIs) were computed for all pooled result analyses. The I² statistic was used to assess heterogeneity among studies. When I² > 50%, a random-effects model was used for analyses, whereas a fixed-effects model was otherwise used. Potential sources of heterogeneity were identified through sensitivity and subgroup analyses.

3. Results

3.1. Study characteristics

The PRISMA flow diagram was shown in Fig. 1. Our search strategy identified 165 potentially studies, of which 13 were not peer-reviewed and failed to define AKI, 32 failed to report AKI or RRT outcomes in patients, 50 with wrong design and 12 utilized data from the same source. The remaining 58 studies of 22,671 patients were included in the

present meta-analysis [8,13–69]. Individual studies incorporated 7 – 5700 patients, with average patient ages ranging from 37 to 79.7 years (Table 1). The Newcastle-Ottawa scale was used to assess the quality of these included studies (Table 2). Studies came from China (n = 29), the USA (n = 12), Italy (n = 3), the UK (n = 2), Spain (n = 2), Kuwait (n = 2), France (n = 1), Germany (n = 1), Canada (n = 1), Thailand (n = 1), India (n = 1), Poland (n = 1) and Turkey (n = 1). One study included data from 12 countries. All studies were observational in nature, including 54 retrospective studies and 4 prospective studies. Of these studies, 15 were multi-center analyses.

3.2. Clinical outcomes

3.2.1. Acute kidney injury

Incidence of AKI among COVID-19 patients was reported in 51 of the included studies. Of the 21,531 patients included in these studies, 4121 developed AKI, with a pooled AKI incidence rate of 12.3% among COVID-19 patients (95% CI 9.5–15.6%, $I^2 = 97\%$) (Fig. 2a). In an effort to identify sources of heterogeneity among included studies, a sensitivity analysis was conducted which failed to identify the drivers of such heterogeneity. As AKI incidence was highest among kidney transplant recipients, we additionally conducted a subgroup analysis, which revealed that the incidence of AKI among transplant patients was 38.9% (95% CI 27.3–51.9%, $I^2 = 67\%$), whereas among non-transplant patients this incidence rate was 9.8% (95% CI 7.4–12.9%, $I^2 = 98\%$) (Fig. 2b).

Three continents were included in our study: Asia, North America



Fig. 2e. Forest plot depicting the incidence of AKI in COVID-19 patients in the USA.

Study	Events	Total				Proportion	95%-Cl	Weight
Wang 2020	3	36 -	- i			0.083	[0.018: 0.225]	7.7%
Wang 2020	0	11 🖻				0.000	[0.000; 0.285]	4.1%
Huang 2020	3	13		_		0.231	[0.050; 0.538]	7.4%
Yang 2020	15	52				0.288	[0.171; 0.431]	8.9%
Arentz 2020	4	21				0.190	[0.054; 0.419]	7.9%
Lei 2020	2	15 -				0.133	[0.017; 0.405]	6.9%
Hu 2020	10	26				0.385	[0.202; 0.594]	8.6%
Argenziano 2020	184	236				0.780	[0.721; 0.831]	9.3%
Husain-Syed 2020	10	12			,	- 0.833	[0.516; 0.979]	6.8%
Rubin 2020	57	71		-		0.803	[0.691; 0.888]	9.0%
Yang 2020	19	66				0.288	[0.183; 0.413]	9.0%
Gaetano 2020	24	61		_		0.393	[0.271; 0.527]	9.1%
Pongpirul 2020	5	6	+		,	- 0.833	[0.359; 0.996]	5.4%
Random effects model	_	626		=-,		0.390	[0.232; 0.576]	100.0%
Heterogeneity: $I^2 = 92\%$, τ^2	² = 1.5616	, p < 0.b	1 ' '	I	I	I		
		0	0.2 0.4	0.6	0.8	1		

Fig. 2f. Forest plot depicting the incidence of AKI in intensive care unit Patients.

Study Events Total Proportion 95%-CI Weight Richardson 2020 347 0.627 [0.586; 0.668] 9.5% 553 Chen 2020 28 0.248 [0.171: 0.338] 9.0% 113 Yang 2020 12 32 0.375 [0.211: 0.563] 8.0% Zhou 2020 27 54 0.500 [0.361; 0.639] 8.7% 0.183 [0.116: 0.269] Dena 2020 20 109 8.8% Wang 2020 [0.488: 0.909] 14 19 0.737 6.9% Brill 2020 54 0.312 [0.244; 0.387] 173 9.2% Nowak 2020 10 46 0.217 [0.109; 0.364] 8.1% Crespo 2020 5 7 0.714 [0.290; 0.963] 4.8% Borobia 2020 120 460 0.261 [0.221; 0.304] 9.4% Cravedi 2020 26 46 0.565 [0.411: 0.711] 8.5% Wang 2020 80 133 0.602 [0.513; 0.685] 9.2% Random effects model 1745 0.420 [0.303; 0.547] 100.0% Heterogeneity: $I^2 = 95\%$, $\tau^2 = 0.7076$, p < 0.010 0.2 0.4 0.6 0.8 1

Fig. 2g. Forest plot depicting the incidence of AKI in deaths.

and Europe, and we conducted a subgroup analysis according to different continents, the AKI incidence was lower in Asia [6.9% (95% CI 4.8–9.6%, $I^2 = 92\%$)] compared to Europe [22.9% (95% CI 12.1–38.9%, $I^2 = 97\%$)] and North America [34.6% (95% CI 24.9–45.7%, $I^2 = 98\%$)] (Fig. 2c). Meanwhile, most of the studies came from China and the USA,

the AKI incidence was lower in 6858 Chinese patients [6.5% (95% CI 4.5–9.2%, $I^2 = 92\%$)] compared to 9880 American patients [34.6% (95% CI 24.9–45.7%, $I^2 = 98\%$)] (Fig. 2d) (Fig. 2e).

In total, 13 studies reported on AKI incidence among ICU patients. Overall, AKI occurred in 312/565 patients admitted to the ICU for an

Study	Events	Total	Proportion	95%-Cl Weight
Wang 2020	2	138 💻	0.014 [0.002; 0.051] 2.0%
Richardson 2020	225	5700 🔹	0.039 [0.035; 0.045] 3.5%
Huang 2020	3	41	0.073 [0.015; 0.199] 2.3%
Chen 2020	3	274 🛨	0.011 [0.002; 0.032] 2.3%
Guan 2020	9	1099 🔹	0.008 [0.004; 0.015] 3.0%
Alberici 2020	1	20 -	0.050 [0.001; 0.249] 1.4%
Yang 2020	9	52 :	0.173 [0.082; 0.303] 2.9%
Zhou 2020	10	191 +	0.052 [0.025; 0.094] 3.0%
Chen 2020	9	99 +	0.091 [0.042; 0.166] 3.0%
Lei 2020	1	34	0.029 [0.001; 0.153] 1.4%
Shi 2020	2	416	0.005 [0.001; 0.017] 2.0%
Wang 2020	4	107	0.037 [0.010; 0.093] 2.5%
Zhang 2020	5	221 -	0.023 [0.007; 0.052] 2.7%
Zhang 2020	0	645 🖻	0.000 [0.000; 0.006] 0.9%
Hu 2020	72	323	0.223 [0.179; 0.272] 3.4%
Salacup 2020	24	242	0.099 [0.065; 0.144] 3.3%
Piva 2020	1	29	0.034 [0.001; 0.178] 1.4%
Argenziano 2020	117	850 -	0.138 [0.115; 0.163] 3.4%
Haydar 2020	26	242	0.107 [0.071; 0.153] 3.3%
Wan 2020	5	135	0.037 [0.012; 0.084] 2.7%
Nowak 2020	1	169 🕂 :	0.006 [0.000; 0.033] 1.4%
Goyal 2020	18	375	0.048 [0.029; 0.075] 3.2%
Anish 2020	16	117	0.137 [0.080; 0.213] 3.2%
Hardy 2020	2	15	0.133 [0.017; 0.405] 1.9%
Crespo 2020	3	15	0.200 [0.043; 0.481] 2.2%
Husain-Syed 2020	3	23	0.130 [0.028; 0.336] 2.2%
Akalin 2020	6	28	0.214 [0.083; 0.410] 2.7%
Wang 2020	9	344	0.026 [0.012; 0.049] 3.0%
Li 2020	7	193	0.036 [0.015; 0.073] 2.9%
Zheng 2020	5	34	0.147 [0.050; 0.311] 2.6%
Rubin 2020	10	71	0.141 [0.070; 0.244] 3.0%
Almazeedi 2020	5	1096	0.005 [0.001; 0.011] 2.7%
Yang 2020	10	463 +	0.022 [0.010; 0.039] 3.0%
Ayed 2020	21	103	0.204 [0.131; 0.295] 3.2%
Gaetano 2020	5	307 =	0.016 [0.005; 0.038] 2.7%
Shi 2020	1	134	0.007 [0.000; 0.041] 1.4%
Lubetzky 2020	5	39	0.128 [0.043; 0.274] 2.6%
Chan 2020	280	3235	0.087 [0.077; 0.097] 3.5%
Xu 2020	4	45	0.089 [0.025; 0.212] 2.5%
Random effects model		17664 📥	0.054 [0.040; 0.071] 100.0%
Heterogeneity: I^2 = 93%, τ^2	⁻ = 0.6731,	p < 0.01	_	
		0 0.1 0.2 0.3 0.4 0.	5	

Fig. 3a. Forest plot depicting the incidence of RRT use in COVID-19 patients.

overall pooled incidence rate of 39.0% (95% CI 23.2–57.6%, $I^2 = 92\%$) (Fig. 2f). A total of 12 studies reported on AKI incidence among deceased patients, of whom 743/1745 exhibited signs of AKI for an incidence rate of 42.0% (95% CI 30.3–54.7%, $I^2 = 95\%$) (Fig. 2g). Furthermore, in seven studies [17,50,51,54,59,63,66], AKI patients were divided into three stages according to the Kidney Disease: Improving Global Outcomes (KDIGO) guideline, among 1588 AKI patients, the proportions of stage 1, 2 and 3 AKI were 36.3%, 20.7%, 43.0%, respectively.

3.2.2. Renal replacement therapy

Data pertaining to the use of RRT among COVID-19 patients was reported in 39 of the studies included in the present meta-analysis. In total, RRT was used to treat 939 out of 17,664 COVID-19 patients in these studies, for a pooled application rate of 5.4% (95% CI 4.0–7.1%, $I^2 = 93\%$) (Fig. 3a). Sensitivity analyses did not result in any meaningful changes in the high heterogeneity observed among the included studies. Subgroup analyses revealed that RRT was used in 15.6% of transplant patients (95% CI 9.9–23.8%, $I^2 = 0\%$) and in 4.8% of non-transplant

patients (95% CI 3.5–6.4%, $I^2 = 93\%$) (Fig. 3b).

In total, 12 studies reported on RRT use among COVID-19 patients admitted to the ICU. Overall, RRT use was reported for 162/776 of these patients for a pooled incidence rate of 16.3% (95% CI 11.1–23.3%, $I^2 = 75\%$) (Fig. 3c).

4. Discussion

We found that rates of AKI (12.3%) and RRT use (5.4%) were high among COVID-19 patients, the AKI incidence was lower in Asia (6.9%) compared to Europe (22.9%) and North America (34.6%). We also found that patients admitted to the ICU exhibited very high rates of AKI (39.0%) and RRT use (16.3%). This meta-analysis also reported the rates of AKI (38.9%) and RRT use (15.6%) among kidney transplant patients. While we were unable to specifically establish rates of mortality among AKI patients, we did determine that AKI was common among patients that died of COVID-19 (42.0%).

AKI development in COVID-19 patients may be driven by several

Study	Events	Total		Proportion	95%-CI	Weight				
subgroup = non-kidney	subgroup = non-kidney transplant recipients									
Wang 2020	2	138 🛨		0.014	[0.002; 0.051]	2.0%				
Richardson 2020	225	5700		0.039	[0.035; 0.045]	3.5%				
Huang 2020	3	41 —	1	0.073	[0.015; 0.199]	2.3%				
Chen 2020	3	274 🛨		0.011	[0.002; 0.032]	2.3%				
Guan 2020	9	1099 🖿		0.008	[0.004; 0.015]	3.0%				
Yang 2020	9	52		0.173	[0.082; 0.303]	2.9%				
Zhou 2020	10	191 🚽	-	0.052	[0.025; 0.094]	3.0%				
Chen 2020	9	99 -		0.091	[0.042; 0.166]	3.0%				
Lei 2020	1	34 💻		0.029	[0.001; 0.153]	1.4%				
Shi 2020	2	416 🔤		0.005	[0.001; 0.017]	2.0%				
Wang 2020	4	107 -	—	0.037	[0.010; 0.093]	2.5%				
Zhang 2020	5	221 🛨		0.023	[0.007; 0.052]	2.7%				
Zhang 2020	0	645 🗈		0.000	[0.000; 0.006]	0.9%				
Hu 2020	72	323		0.223	[0.179; 0.272]	3.4%				
Salacup 2020	24	242		0.099	[0.065; 0.144]	3.3%				
Piva 2020	1	29 💻		0.034	[0.001; 0.178]	1.4%				
Argenziano 2020	117	850	-	0.138	[0.115; 0.163]	3.4%				
Haydar 2020	26	242	— •	0.107	[0.071; 0.153]	3.3%				
Wan 2020	5	135 🕂	—	0.037	[0.012; 0.084]	2.7%				
Nowak 2020	1	169 🛨		0.006	[0.000; 0.033]	1.4%				
Goyal 2020	18	375 🛨		0.048	[0.029; 0.075]	3.2%				
Anish 2020	16	117		0.137	[0.080; 0.213]	3.2%				
Husain-Syed 2020	3	23		0.130	[0.028; 0.336]	2.2%				
Wang 2020	9	344 +		0.026	[0.012; 0.049]	3.0%				
Li 2020	7	193 🛨		0.036	[0.015; 0.073]	2.9%				
Zheng 2020	5	34	-	0.147	[0.050; 0.311]	2.6%				
Rubin 2020	10	71		0.141	[0.070; 0.244]	3.0%				
Almazeedi 2020	5	1096		0.005	[0.001; 0.011]	2.7%				
Yang 2020	10	463 🖿		0.022	[0.010; 0.039]	3.0%				
Ayed 2020	21	103		0.204	[0.131; 0.295]	3.2%				
Gaetano 2020	5	307 =		0.016	[0.005; 0.038]	2.7%				
Shi 2020	1	134 ≝−	-	0.007	[0.000; 0.041]	1.4%				
Chan 2020	280	3235		0.087	[0.077; 0.097]	3.5%				
XU 2020	4	45		0.089	[0.025; 0.212]	2.5%				
Random effects model	2	1/54/	•	0.048	[0.035; 0.064]	89.3%				
Heterogeneity: I^{-} = 93%, τ^{-}	= 0.6780,	p < 0.01								
subgroup = kidney tran	splant re	cipients								
Alberici 2020	1	20 —		0.050	[0.001; 0.249]	1.4%				
Hardy 2020	2	15 —		0.133	[0.017; 0.405]	1.9%				
Crespo 2020	3	15 -		0.200	[0.043; 0.481]	2.2%				
Akalin 2020	6	28		0.214	[0.083; 0.410]	2.7%				
Lubetzky 2020	5	39		0.128	[0.043; 0.274]	2.6%				
Random effects model		117	\sim	0.156	[0.099; 0.238]	10.7%				
Heterogeneity: $I^2 = 0\%$, τ^2	= 0, p = 0.6	61								
Random effects model		17664	>	0.054	[0.040; 0.071]	100.0%				
Heterogeneity: $I^2 = 93\%$, τ^2	[′] = 0.6731,	p < 0.01		I	-					
Residual heterogeneity: 12	= 93%, p <	0.01 0	0.1 0.2 0.3 0.4 (0.5						

Fig. 3b. Subgroup analysis depicting the incidence of RRT use in COVID-19 patients.

mechanisms. For one, the virus may directly infect and damage renal cells. SARS-CoV-2 utilizes ACE2 as a cell entry receptor [70], and in humans, ACE2 is expressed on proximal tubular cells and podocytes [71,72]. A postmortem analysis of postmortem renal histopathology in 26 COVID-19 patients conducted in China detected the presence of coronavirus particles within proximal tubular cells and podocytes, with these particles coinciding with diffuse acute proximal tubular injury and occasional podocyte vacuolation [73]. In a systematic review involving 11 studies, the positive rate of SARS-CoV-2 viral RNA in urine of 195 patients was 5.74% [10]. SARS-CoV-2 viral particles also have been

detected in patient's blood, with an average period of one week between virus detection in the blood and AKI, suggesting that direct renal infection may be a key process driving the incidence of this dangerous condition [16,19,74,75]. Another study found that SARS-CoV-2 may also be able to enter target cells using CD147, which is highly expressed in the kidneys, as a cell surface receptor [76,77]. In critically ill patients, sepsis is also thought to be the primary driver of AKI incidence [78], and is common in deceased COVID-19 patients [18,22]. Indeed, up to 20% of severe hospitalized COVID-19 patients develop viral sepsis and acute respiratory distress syndrome (ARDS) [79]. In individuals suffering from



Fig. 3c. Forest plot depicting the incidence of RRT use in intensive care unit Patients.

sepsis, hypoxia-related acute tubular necrosis (ATN) and severe hyperinflammation can drive AKI development [80]. Such hyperinflammation is closely associated with cytokine release syndrome (CRS), which results in intrarenal inflammation and increased vascular permeability [81]. CRS has frequently been detected among COVID-19 patients, with particularly elevated levels of IL-6 having bene detected in affected individuals [16,82]. Organ crosstalk may also govern AKI pathogenesis. Indeed, ARDS and associated hypoxemia, inflammation, and the need for mechanical ventilation can result in the degradation of kidney hemodynamics and functionality [83]. Annat et al [84] found that continuous positive pressure ventilation (CPPV) was sufficient to decrease urine output, glomerular filtration rate (GFR), and renal blood flow (RBF), potentially resulting in AKI. Drug- or hyperventilationrelated rhabdomyolysis can also result in tubular toxicity, and analyses of COVID-19 patient renal histopathology have suggested that rhabdomyolysis may be a disease-related complication as evidenced by the presence of pigmented casts within tubules and increased levels of creatine phosphokinase [73]. Ultimately, a number of pathogenic factors are likely to contribute to the incidence and severity of AKI in individuals suffering from COVID-19.

There are multiple limitations to the present study. For one, some of these outcomes were associated with high heterogeneity that may be attributable to the diverse COVID-19 incidence rates and treatment approaches in different countries, as well as to differences in study design and mutation-related changes in viral virulence. In addition, the definition of AKI was not always clear as it was generally not the main study outcome. As such, only pre-print studies that explicitly define AKI and published studies were included in this analysis. Furthermore, the majority of the studies included in this meta-analysis were conducted in China, and their applicability to other regions remains to be established.

In summary, AKI frequently occurs among patients suffering from COVID-19 and is most common among severely ill patients and among those that ultimately succumb to this disease. It is thus essential that the incidence of AKI be identified as quickly as possible in these patients so that RRT and other treatments can be initiated as appropriate in an effort. We believe that the present study will underscore the severity of AKI rates among COVID-19 patients, while emphasizing the need for further clinical studies of this severe complication.

Funding

None.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary material

Supplementary data to this article can be found online at https://doi.org/10.1016/j.intimp.2020.107159.

References

- [1] C. Drosten, S. Günther, W. Preiser, S. van der Werf, H.R. Brodt, S. Becker, et al., Identification of a Novel Coronavirus in patients with severe acute respiratory syndrome, N. Engl. J. Med. 348 (20) (2003) 1967–1976, https://doi.org/10.1056/ NEJMoa030747.
- [2] A.M. Zaki, S. van Boheemen, T.M. Bestebroer, A.D. Osterhaus, R.A. Fouchier, Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia, N. Engl. J. Med. 367 (19) (2012) 1814–1820, https://doi.org/10.1056/ NEJMoa1211721.
- [3] V.J. Munster, M. Koopmans, N. van Doremalen, D. van Riel, E. de Wit, Novel Coronavirus emerging in China -key questions for impact assessment, N. Engl. J. Med. 3828 (8) (2020), https://doi.org/10.1056/NEJMp2000929.
- [4] COVID-19 Data Repository by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. https://github.com/CSSEGISandData /COVID-19, 2020 [accessed 31 July 2020].
- [5] P. Zhou, X.L. Yang, X.G. Wang, B. Hu, L. Zhang, W. Zhang, et al., A pneumonia outbreak associated with a new coronavirus of probable bat origin, Nature 579 (7798) (2020) 270–273, https://doi.org/10.1038/s41586-020-2012-7.
- [6] K.H. Chu, W.K. Tsang, C.S. Tang, M.F. Lam, F.M. Lai, K.F. To, et al., Acute renal impairment in coronavirus-associated severe acute respiratory syndrome, Kidney Int. 67 (2) (2005) 698–705, https://doi.org/10.1111/j.1523-1755.2005.67130.x.
- [7] X. Xu, P. Chen, J. Wang, J. Feng, H. Zhou, X. Li, et al., Evolution of the novel coronavirus from the ongoing Wuhan outbreak and modeling of its spike protein for risk of human transmission, Sci. China Life Sci. 63 (3) (2020) 457–460, https:// doi.org/10.1007/s11427-020-1637-5.
- [8] Z. Li, M. Wu, J.W. Yao, J. Guo, X. Liao, S.J. Song, et al., Caution on kidney dysfunctions of COVID-19 patients, medRxiv (2020), https://doi.org/10.2139/ ssrn.3559601.
- [9] H. Ali, A. Daoud, M.M. Mohamed, S.A. Salim, L. Yessayan, J. Baharani, et al., Survival rate in acute kidney injury superimposed COVID-19 patients: a systematic review and meta-analysis, Ren. Fail. 42 (1) (2020) 393–397, https://doi.org/ 10.1080/0886022X.2020.1756323.
- [10] V.W. Chan, P.K. Chiu, C.H. Yee, Y. Yuan, C.F. Ng, J.Y. Teoh, A systematic review on COVID-19: urological manifestations, viral RNA detection and special considerations in urological conditions, World J. Urol. 10223 (2020), https://doi. org/10.1007/s00345-020-03246-4.
- [11] M. Vrabel, Preferred reporting items for systematic reviews and meta-analyses, Oncol. Nurs. Forum 42 (5) (2015) 552–554, https://doi.org/10.1188/15.ONF.552-554.
- [12] F.S. Donna, A.B. Jesse, C.M. Sally, O. Ingram, G.D. Williamson, R. Drummond, et al., Meta-analysis of observational studies in epidemiology, JAMA 283 (15) (2000) 2008–2012.

- [13] D. Wang, B. Hu, C. Hu, F. Zhu, X. Liu, J. Zhang, et al., Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected Pneumonia in Wuhan, China, JAMA 323 (11) (2020), https://doi.org/10.1001/jama.2020.1585.
- [14] L.W. Wang, X. Li, H. Chen, S.N. Yan, D. Li, Y. Li, et al., Coronavirus disease 19 infection does not result in acute kidney injury: an analysis of 116 hospitalized patients from Wuhan, China, Am. J. Nephrol. 51 (5) (2020) 343–348, https://doi.org/10.1159/000507471.
- [15] S. Richardson, J.S. Hirsch, M. Narasimhan, J.M. Crawford, T. McGinn, K. W. Davidson, et al., Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City Area, JAMA 323 (20) (2020), https://doi.org/10.1001/jama.2020.6775.
- [16] C.L. Huang, Y.M. Wang, X.W. Li, L.L. Ren, J.P. Zhao, Y. Hu, et al., Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China, Lancet 395 (10223) (2020) 497–506, https://doi.org/10.1016/S0140-6736(20)30183-5.
- [17] Y.C. Cheng, R. Luo, K. Wang, M. Zhang, Z.X. Wang, L. Dong, et al., Kidney disease is associated with in-hospital death of patients with COVID-19, Kidney Int. 97 (5) (2020) 829–838, https://doi.org/10.1016/j.kint.2020.03.005.
- [18] T. Chen, D. Wu, H.L. Chen, W.M. Yan, D.L. Yang, G. Chen, et al., Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study, BMJ (online) 368 (2020) 368, https://doi.org/10.1136/bmj. m1091.
- [19] W.J. Guan, Z.Y. Ni, Y. Hu, W.H. Liang, C.Q. Ou, J.X. He, et al., Clinical characteristics of coronavirus disease 2019 in China, N. Engl. J. Med. 382 (18) (2020) 1708–1720, https://doi.org/10.1056/NEJMoa2002032.
- [20] F. Alberici, E. Delbarba, C. Manenti, L. Econimo, F. Valerio, A. Pola, et al., A single center observational study of the clinical characteristics and short-term outcome of 20 kidney transplant patients admitted for SARS-CoV2 pneumonia, Kidney Int. 97 (6) (2020) 1083–1088, https://doi.org/10.1016/j.kint.2020.04.002.
- [21] X. Yang, Y. Yu, J. Xu, H. Shu, J. Xia, H. Liu, et al., Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a singlecentered, retrospective, observational study, Lancet Respiratory Med. 8 (5) (2020) 475–481, https://doi.org/10.1016/S2213-2600(20)30079-5.
- [22] F. Zhou, T. Yu, R. Du, G. Fan, Y. Liu, Z. Liu, et al., Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet 395 (10229) (2020) 1054–1062, https://doi.org/ 10.1016/S0140-6736(20)30566-3.
- [23] N. Chen, M. Zhou, X. Dong, J. Qu, F. Gong, Y. Han, et al., Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study, The Lancet 395 (10223) (2020) 507–513, https://doi. org/10.1016/S0140-6736(20)30211-7.
- [24] M. Arentz, E. Yim, L. Klaff, S. Lokhandwala, F.X. Riedo, M. Chong, et al., Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State, JAMA (2020), https://doi.org/10.1001/jama.2020.4326.
- [25] D. Banerjee, J. Popoola, S. Shah, I.C. Ster, V. Quan, M. Phanish, COVID-19 infection in kidney transplant recipients, Kidney Int. 97 (6) (2020) 1076–1082, https://doi.org/10.1016/j.kint.2020.03.018.
- [26] Y. Deng, W. Liu, K. Liu, Y.Y. Fang, J. Shang, L. Zhou, et al., Clinical characteristics of fatal and recovered cases of coronavirus disease 2019 in Wuhan, China: a retrospective study, Chin. Med. J. 133 (11) (2020) 1261–1267, https://doi.org/ 10.1097/CM9.0000000000824.
- [27] T. Guo, Y. Fan, M. Chen, X. Wu, L. Zhang, T. He, et al., Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA, Cardiology 5 (7) (2020), https://doi.org/10.1001/jamacardio.2020.1017.
 [28] S. Lei, F. Jiang, W. Su, C. Chen, J. Chen, W. Mei, et al., Clinical characteristics and
- [28] S. Lei, F. Jiang, W. Su, C. Chen, J. Chen, W. Mei, et al., Clinical characteristics and outcomes of patients undergoing surgeries during the incubation period of COVID-19 infection, E Clin. Med. 21 (2020), https://doi.org/10.1016/j. eclinm.2020.100331.
- [29] S. Shi, M. Qin, B. Shen, Y. Cai, T. Liu, F. Yang, et al., Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA, Cardiology 5 (7) (2020), https://doi.org/10.1001/jamacardio.2020.0950.
- [30] D.W. Wang, Y.M. Yin, C. Hu, X. Liu, X.G. Zhang, S.L. Zhou, et al., Clinical course and outcome of 107 patients infected with the novel coronavirus, SARS-CoV-2, discharged from two hospitals in Wuhan, China, Crit. Care 24 (1) (2020), https:// doi.org/10.1186/s13054-020-02895-6.
- [31] G. Zhang, C. Hu, L. Luo, F. Fang, Y. Chen, J. Li, et al., Clinical features and shortterm outcomes of 221 patients with COVID-19 in Wuhan, China, J. Clin. Virol. 127 (2020), https://doi.org/10.1016/j.jcv.2020.104364.
- [32] X.L. Zhang, H. Cai, J.H. Hu, J.S. Lian, J.Q. Gu, S.Y. Zhang, et al., Epidemiological, clinical characteristics of cases of SARS-CoV-2 infection with abnormal imaging findings, Int. J. Infect. Dis. 94 (2020) 81–87, https://doi.org/10.1016/j. ijidi.2020.03.040.
- [33] L. Hu, S. Chen, Y. Fu, Z. Gao, H. Long, J.M. Wang, et al., Risk factors associated with clinical outcomes in 323 COVID-19 hospitalized patients in Wuhan, China, Clin. Infect. Dis. (2020), https://doi.org/10.1093/cid/ciaa539.
- [34] S.E. Brill, H.C. Jarvis, E. Ozcan, T.L.P. Burns, R.A. Warraich, L.J. Amani, et al., COVID-19: a retrospective cohort study with focus on the over-80s and hospitalonset disease, BMC Med. 18 (1) (2020), https://doi.org/10.1186/s12916-020-01665-z.
- [35] Z.B. Cheung, D.A. Forsh, Early outcomes after hip fracture surgery in COVID-19 patients in New York City, J. Orthopaedics 21 (2020) 291–296, https://doi.org/ 10.1016/j.jor.2020.06.003.
- [36] G. Salacup, K.B. Lo, F. Gul, E. Peterson, R.D. Joy, R. Bhargav, et al., Characteristics and clinical outcomes of COVID-19 patients in an underserved-inner city population: A single tertiary center cohort, J. Med. Virol. (2020), https://doi.org/ 10.1002/jmv.26252.

- [37] S. Piva, M. Filippini, F. Turla, S. Cattaneo, A. Margola, S. De Fulviis, et al., Clinical presentation and initial management critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in Brescia, Italy, J. Critical Care 58 (2020) 29–33, https://doi.org/10.1016/j.jcrc.2020.04.004.
- [38] M.G. Argenziano, S.L. Bruce, C.L. Slater, J.R. Tiao, M.R. Baldwin, R.G. Barr, et al., Characterization and clinical course of 1000 patients with coronavirus disease 2019 in New York: retrospective case series, BMJ (2020), https://doi.org/10.1136/ bmj.m1996.
- [39] A.R. Mitra, N.A. Fergusson, E. Lloyd-Smith, A. Wormsbecker, D. Foster, A. Karpov, et al., Baseline characteristics and outcomes of patients with COVID-19 admitted to intensive care units in Vancouver, Canada: a case series, Can. Med. Assoc. J. 192 (26) (2020) E694–E701, https://doi.org/10.1503/cmaj.200794.
- [40] A. Aggarwal, A. Shrivastava, A. Kumar, A. Ali, Clinical and epidemiological features of SARS-CoV-2 patients in SARI ward of a tertiary care centre in New Delhi, J. Assoc. Physicians India 68 (2020).
- [41] A. Haydar, K.B. Lo, A. Goyal, F. Gul, E. Peterson, R. Bhargav, et al., Palliative care utilization among patients with COVID-19 in an underserved population: a singlecenter retrospective study, J. Pain Symptom Manage. 60 (2) (2020) e18–e21, https://doi.org/10.1016/j.jpainsymman.2020.05.022.
- [42] H. Yi, F. Lu, X. Jin, R. Chen, B. Liu, X. Dong, et al., Clinical characteristics outcomes of coronavirus disease 2019 infections among diabetics: a retrospective and multicenter study in China, J. Diabetes (2020), https://doi.org/10.1111/1753-0407.13098.
- [43] S. Wan, Y. Xiang, W. Fang, Y. Zheng, B. Li, Y. Hu, et al., Clinical features and treatment of COVID-19 patients in northeast Chongqing, J. Med. Virol. 92 (7) (2020) 797–806, https://doi.org/10.1002/jmv.25783.
- [44] B. Nowak, P. Szymański, I. Pańkowski, A. Szarowska, K. Życińska, W. Rogowski, et al., Clinical characteristics and short-term outcomes of coronavirus disease 2019: retrospective, single-center experience of designated hospital in Poland. Polish, Arch. Intern. Med. (2020), https://doi.org/10.20452/pamw.15361.
- [45] P. Goyal, J.J. Choi, L.C. Pinheiro, et al., Clinical characteristics of Covid-19 in New York City, N. Engl. J. Med. 382 (2020) 2372–2374, https://doi.org/10.1056/ NEJMc2010419.
- [46] Early Description of Coronavirus 2019 Disease in Kidney Transplant Recipients in New York. J. Am. Soc. Nephrol. 31(6) (2020) 1150–1156. https://doi.org/ 10.1681/ASN.2020030375.
- [47] M. Crespo, M.J. Pérez-Sáez, D. Redondo-Pachón, L. Llinàs-Mallol, M.M. Montero, J. Villar-García, et al., COVID-19 in elderly kidney transplant recipients, Am. J. Transplant. (2020), https://doi.org/10.1111/AJT.16096.
- [48] A. Borobia, A. Carcas, F. Arnalich, R. Álvarez-Sala, J. Monserrat-Villatoro, M. Quintana, et al., A cohort of patients with COVID-19 in a major teaching hospital in Europe, J. Clin. Med. 9 (6) (2020), https://doi.org/10.3390/ jcm9061733.
- [49] P. Cravedi, S.M. Suraj, Y. Azzi, M. Haverly, S. Farouk, M.J. Perez-Saez, et al., COVID-19 and kidney transplantation: results from the TANGO international transplant consortium, Am. J. Transplant. (2020), https://doi.org/10.1111/ ajt.16185.
- [50] F. Husain-Syed, J. Wilhelm, S. Kassoumeh, H.W. Birk, S. Herold, I. Vadasz, et al., Acute kidney injury and urinary biomarkers in hospitalized patients with coronavirus disease-2019, Nephrol. Dial. Transplant. 35 (7) (2020) 1271–1274, https://doi.org/10.1093/ndt/gfaa162.
- [51] V. Nair, N. Jandovitz, J.S. Hirsch, G. Nair, M. Abate, M. Bhaskaran, et al., COVID-19 in kidney transplant recipients, Am. J. Transplant. 20 (7) (2020) 1819–1825, https://doi.org/10.1111/ajt.15967.
- [52] A. Enver, A. Yorg, B. Rachel, S. Harish, P. Michael, H. Vagish, Covid-19 and kidney transplantation, N. Engl. J. Med (2020), https://doi.org/10.1056/NEJMc2011117.
- [53] Y. Wang, X.F. Lu, Y.S. Li, H. Chen, T.G. Chen, N. Su, et al., Clinical course and outcomes of 344 intensive care patients with COVID-19, Am. J. Respir. Crit. Care Med. 201 (11) (2020) 1430–1434, https://doi.org/10.1164/rccm.202003-0736LE.
- [54] E. Demir, M. Uyar, E. Parmaksiz, A. Sinangil, B. Yelken, A.B. Dirim, et al., COVID-19 in kidney transplant recipients: A multicenter experience in Istanbul, e13371, Transpl. Infect. Dis. (2020), https://doi.org/10.1111/tid.13371.
- [55] W. Zhao, S.K. Yu, X.Y. Zha, N. Wang, Q.M. Pang, D.Z. Li, et al., Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study, medRxiv (2020), https://doi.org/10.1101/ 2020.03.13.20035436.
- [56] G.H. Xiao, H.B. Hu, F. Wu, T. Sha, Q.B. Huang, H.J. Li, et al., Acute kidney injury in patients hospitalized with COVID-19 in Wuhan, China: A single-center retrospective observational study, medRxiv. (2020), https://doi.org/10.1101/ 2020.04.06.20055194.
- [57] X.F. Jiang, J.X. Tao, H. Wu, Y.X. Wang, W. Zhao, M. Zhou, et al., Clinical features and management of severe COVID-19: A retrospective study in Wuxi, Jiangsu Province, China, medRxiv (2020), https://doi.org/10.1101/ 2020.04.10.20060335.
- [58] Y. Zheng, L.J. Sun, M. Xu, J. Pan, Y.T. Zhang, X.L. Fang, et al., Clinical characteristics of 34 COVID-19 patients admitted to ICU in Hangzhou, China, medRxiv (2020), https://doi.org/10.1101/2020.04.12.20062604.
- [59] S. Rubin, A. Orieux, R. Prevel, A. Garric, M.-L. Bats, S. Dabernat, et al. Characterisation of acute kidney injury in critically III patients with severe coronavirus disease-2019 (COVID-19). medRxiv 2020. https://doi.org/10.1101/ 2020.05.06.20069872.2020.
- [60] S. Almazeedi, S. Al Youha, M.H. Jamal, M. Al-Haddad, A. Al-Muhaini, F. Al-Ghimlas, et al., Clinical characteristics, risk factors and outcomes among the first consecutive 1,096 patients diagnosed with COVID-19: The Kuwait Experience, medRxiv (2020), https://doi.org/10.1101/2020.05.09.20096495.

- [61] S. Yang, L. Ma, Y.-L. Wang, Q. Wang, Q. Tong, M. Chen, et al., Risk factors for critical-ill events of patients with COVID-19 in Wuhan, China: a retrospective cohort study, medRxiv (2020), https://doi.org/10.1101/2020.06.14.20130765.
- [62] M. Ayed, A. Borahmah, A. Yazdani, A. Sultan, A. Mossad, H. Rawdhan, Assessment of clinical characteristics and mortality-associated factors in COVID-19 Critical cases in Kuwait, medRxiv 2020. https://doi.org/10.1101/2020.06.17.20134007.
- [63] G. Alfano, A. Ferrari, F. Fontana, G. Mori, R. Magistroni, M. Marianna, et al., Incidence, risk factors and mortality outcome in patients with acute kidney injury in COVID-19: a single-center observational study, medRxiv 2020. https://doi.org/ 10.1101/2020.06.24.20138230.
- [64] P.Y. Shi, G.X. Ren, J. Yang, Z.Q. Li, S.J. Deng, M. Li, et al., Clinical characteristics of imported and second-generation COVID-19 cases outside Wuhan, China: A multicenter retrospective study, medRxiv (2020), https://doi.org/10.1101/ 2020.04.19.20071472.
- [65] M. Lubetzky, M. Aull, R. Craig-Shapiro, J. Lee, J. Lee, S. Sultan, et al., Kidney allograft recipients diagnosed with coronavirus disease-2019: a single center report, medRxiv (2020), https://doi.org/10.1101/2020.04.30.20086462.
- [66] L.L. Chan, K. Chaudhary, A. Saha, K. Chauhan, A. Vaid, M. Baweja, et al. Acute kidney injury in hospitalized patients with COVID-19. medRxiv 2020. https://doi. org/10.1101/2020.05.04.20090944.
- [67] W.A. Pongpirul, S. Wiboonchutikul, L. Charoenpong, N. Panitantum, A. Vachiraphan, S. Uttayamakul, et al. Clinical course and potential predicting factors of pneumonia of adult patients with coronavirus disease 2019 (COVID-19): A retrospective observational analysis of 193 confirmed cases in Thailand. medRxiv 2020. https://doi.org/10.1101/2020.06.24.20139642.
- [68] Y.H. Xu, Z.H. Xu, X.S. Liu, L.H. Cai, H.C. Zheng, Y.B. Huang, et al., Clinical findings in critically ill patients infected with SARS-CoV-2 in Guangdong Province, China: a multi-center, retrospective, observational study, medRxiv (2020), https://doi.org/ 10.1101/2020.03.03.20030668.
- [69] S.J. Yan, X.Y. Song, F. Lin, H.Y. Zhu, X.Z. Wang, M. Li, et al., Clinical characteristics of coronavirus disease 2019 in Hainan China, medRxiv (2020), https://doi.org/10.1101/2020.03.19.20038539.
- [70] M. Hoffmann, H. Kleine-Weber, S. Schroeder, N. Krüger, T. Herrler, S. Erichsen, et al., SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell 181 (2) (2020) 271–280.e278, https://doi.org/10.1016/j.cell.2020.02.052.
- [71] X. Zou, K. Chen, J.W. Zou, P.Y. Han, J. Hao, Z.G. Han, Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection, Front. Med. 14 (2) (2020) 185–192, https://doi.org/10.1007/s11684-020-0754-0.
- [72] V. Monteil, H. Kwon, P. Prado, A. Hagelkrüys, R.A. Wimmer, M. Stahl, et al., Inhibition of SARS-CoV-2 infections in engineered human tissues using clinical-

grade soluble human ACE2, Cell 181 (4) (2020) 905–913.e907, https://doi.org/ 10.1016/j.cell.2020.04.004.

- [73] H. Su, M. Yang, C. Wan, L.X. Yi, F. Tang, H.Y. Zhu, et al., Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China, Kidney Int. 98 (1) (2020) 219–227, https://doi.org/10.1016/j.kint.2020.04.003.
- [74] L. Peng, J. Liu, W.X. Xu, Q.M. Luo, D.B. Chen, Z.Y. Lei, et al., SARS-CoV-2 can be detected in urine, blood, anal swabs, and oropharyngeal swabs specimens, J. Med. Virol. (2020), https://doi.org/10.1002/jmv.25936.
- [75] W.L. Wang, Y. Xu, R. Gao, R.J. Lu, K. Han, G.Z. Wu, et al., Detection of SARS-CoV-2 in different types of clinical specimens, JAMA J. Am. Med. Assoc. 323 (18) (2020), https://doi.org/10.1001/jama.2020.3786.
- [76] K. Wang, W. Chen, Y.S. Zhou, J.Q. Lian, Z. Zhang, P. Du, et al., SARS-CoV-2 invades host cells via a novel route: CD147-spike protein, medRxiv (2020), https://doi.org/ 10.1101/2020.03.14.988345.
- [77] T. Kosugi, K. Maeda, W. Sato, S. Maruyama, K. Kadomatsu, CD147 (EMMPRIN/ Basigin) in kidney diseases: from an inflammation and immune system viewpoint, Nephrol. Dial. Transplant. 30 (7) (2015) 1097–1103, https://doi.org/10.1093/ ndt/gfu302.
- [78] M. Poukkanen, S.T. Vaara, V. Pettila, K.-M. Kaukonen, A.-M. Korhonen, S. Hovilehto, et al., Acute kidney injury in patients with severe sepsis in Finnish Intensive Care Units, Acta Anaesthesiol. Scand. 57 (7) (2013) 863–872, https:// doi.org/10.1111/aas.12133.
- [79] H.C. Prescott, T.D. Girard, Recovery from severe COVID-19 leveraging the lessons of survival from sepsis, JAMA (2020) on 08/22/2020.
- [80] A. Aslan, M.C. van den Heuvel, C.A. Stegeman, E.R. Popa, A.M. Leliveld, G. Molema, et al., Kidney histopathology in lethal human sepsis, Crit. Care 22 (1) (2018) 359, https://doi.org/10.1186/s13054-018-2287-3.
- [81] J.R. Tisoncik, M.J. Korth, C.P. Simmons, J. Farrar, T.R. Martin, M.G. Katze, Into the eye of the cytokine storm, Microbiol. Mol. Biol. Rev. 76 (1) (2012) 16–32, https:// doi.org/10.1128/MMBR.05015-11.
- [82] S. David, Z.L. Inbal, R. Lori, R. Shane, F.W. Carl, A.N. Garry, Levels of the TNFrelated cytokine LIGHT increase in hospitalized COVID-19 patients with cytokine release syndrome and ARDS, Clin. Sci. Epidemiol. 5 (4) (2020), https://doi.org/ 10.1128/mSphere.00699-20.
- [83] M. Darmon, C. Clec'h, C. Adrie, L. Argaud, B. Allaouchiche, E. Azoulay, et al., Acute respiratory distress syndrome and risk of AKI among critically ill patients, Clin. J. Am. Soc. Nephrol. 9 (8) (2014) 1347–1353, https://doi.org/10.2215/ CJN.08300813.
- [84] G. Annat, J.P. Viale, B.B. Xuan, Effect of PEEP ventilation on renal function, plasma renin, aldosterone, neurophysins and urinary ADH, and prostaglandins, Anesthesiology 582 (2) (1983), https://doi.org/10.1097/00000542-198302000-00006.